

BATH INSTITUTE FOR RHEUMATIC DISEASES

England & Wales · Charity number 1040650

Details

Other names BIRD

Status Registered

Legal form Charitable company

Company number [02908933](#)

Registered 1994-09-07

Register [View on the Charity Commission register](#)

Contact

Address D1 Wolfson Building
Royal United Hospital
Combe Park
Bath
BA1 3NG

Phone 01225336363

Email BIRD@birdbath.org.uk

Website www.birdbath.org.uk

Activities

Objects: TO RELIEVE SICKNESS AND TO PROMOTE AND ADVANCE MEDICAL KNOWLEDGE WITH PARTICULAR REFERENCE TO RHEUMATIC DISEASES AND TO UNDERTAKE RESEARCH IN RELATION THERETO AND TO PUBLISH THE USEFUL RESULTS OF SUCH RESEARCH

Activities: To support research and educational activities in bone and joint diseases in Bath

Classification

- **How:** Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Bath And North East Somerset

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£104,454	£240,479	-	-
2024-03-31	£106,886	£238,680	-	-
2023-03-31	£163,447	£244,037	-	-
2022-03-31	£123,786	£180,894	-	-
2021-03-31	£92,719	£224,733	-	-

Trustees

Name	Role	Appointed
Bernard Morley	Chair	2021-05-25
DR RAJ SENGUPTA		2012-12-13
Dr AMANDA MACKENZIE		2012-12-13
Dr Neil McHugh		2018-06-05
Dr William Tillet		2016-03-15
LINDA SNELUS		2022-05-24
MR JIM SHERWIN		
Mr Chris Johns BA MSc		2014-09-30
Shane O'Reilly		2022-09-20

Accounts



CELEBRATING 50 YEARS

Bath Institute for Rheumatic Diseases
Arthritis | Research | Education

Annual Report and Accounts 2024-25



Contents	Page
Charity information	1
Trustees' Annual Report	2
Statement of directors' responsibilities	12
Independent Examiner Report	14
Funds Statements:-	
Statement of Financial Activities	16
Prior Year statement	17
Statement of total recognised gains and losses	18
Income and Expenditure account	20
Balance sheet	21
Notes to the accounts	23

Charity information

The Trustees present their Report and Accounts for the year ended 31 March 2025, which also comprises the Directors' Report required by the Companies Act 2006.

The charity name

The legal name of the charity is:- Bath Institute for Rheumatic Diseases. The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650. The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Department D1
Wolfson Building, Royal United Hospital Bath,
BA1 3NG
Telephone 01225 336363

BIRD@birdbath.org.uk www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office for the period covered by the report:

Chris Johns
Dr Amanda Mackenzie
Prof Neil McHugh
Prof Bernie Morley emeritus - **Chair**
Shane O'Reilly
Prof Raj Sengupta
Jim Sherwin
Linda Snelus
Dr William Tillett

Objects and activities of the charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Strategy

We continue to follow our strategy with the central purpose of balancing reliance on investment performance over the long term with more grant and donor fundraising, which in turn requires a raised profile and clearer articulation of impact.

- **BIRD attended the British Society of Rheumatologists conference for the third time to highlight our work**

- **Reaching record-breaking attendance of 730 healthcare professionals for educational events**

- **Launch of a newly redesigned website in November 2024**

- **BIRD co-hosted the fourth Skin@Bath Network Symposium with 198 participants from 12 countries**

- **BIRD celebrated significant milestones on its 50th anniversary in 2025**

We finish the financial year with **£1,548,091** in funds, down from **£1,791,638** at the same point last year, reflecting the need to draw down additional funds due to the instability in the world stock markets.

BIRD's income totalled **£104,455**, but expenditure was **£240,479**. In total, BIRD awarded almost **£60,000*** in **grants and bursaries** to clinician researchers and early career researchers and spent over **£50,000 on patient and public engagement**.

Grants awarded for research

BIRD funds research projects in rheumatic diseases which:

- **Help to promote and advance medical knowledge**
- **Improve treatments for patients**
- **Encourage collaboration between clinicians and research scientists**
- **Supports the next generation of researchers into bone and joint diseases**

The **focus is on pump prime funding** for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The **guideline for grant** amounts is up to **£20,000** (but greater amounts may be considered) that would be ideally suited to **pilot studies, preliminary research, tests of clinical effectiveness** or would enable other grants to be made for research.

It aims to **promote and advance medical science, pump-priming research**, help **researchers in the early stages of their careers**, help clinicians to be research active, **encourage collaborations** between clinicians and research scientists, and **ensure patients are involved in research**.

*£32,865 after write backs, due to project cancellations.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded **over 30 projects**, with over **700 patients involved in a meaningful way**, helping to advance medical science, with **grants generating at least 30 academic publications so far**.

In total, £54,308 for research was awarded:

£16,376 to Dr Anita McGrogan, Dr Sarah Tansley & Christine MacFadyen for a project on Pregnancy outcomes in Systemic Lupus Erythematosus.

This project aims to better understand specific risks for patients with lupus who are pregnant, including the risk of miscarriage, stillbirth, and congenital malformations. They hope that this will provide valuable information for women in the UK with lupus who are considering pregnancy, allow improved planning for maternity care in lupus and that it will form a basis for future research.

£17,933 to Dr Jen Pearson & Dr Caroline Flurey for a project to understand the experience of men living with Fibromyalgia (FM).

This project aims to understand what it's like to be a man with fibromyalgia, how men manage their condition, and what support they would like from their clinical team. They will look into this by talking to 30-40 men with fibromyalgia either individually or in groups with other men (depending on their preference). Patients in this study will come from one NHS Trust in the UK and will be invited through national charities and social media. This will be the first study in the UK to talk specifically to men with fibromyalgia about their experiences and needs.

£19,999 to Dr Sarah Tansley for the project titled 'Does Immunoprecipitation coupled with high performance liquid chromatography mass spectrometry provide equivalent autoantibody diagnostic capabilities to conventional radio-immunoprecipitation?'

This project will ultimately help answer questions that matter to patients such as 'what does the future hold for me?' Autoantibodies (AAb) are a blood test used by doctors to help diagnose rheumatic diseases like myositis and scleroderma. Different AAb are linked to different diseases and to complications like lung disease and cancer. The AAb tests used by hospitals don't always work well and often give the wrong result. Missed AAb can delay diagnosis and prevent personalised care. The best AAb test is called radio-immunoprecipitation. This test is accurate but time- consuming, expensive, and not widely available. A new test called immunoprecipitation-mass spectrometry (IP-MS) could overcome these problems. So far IP-MS has only been used by one research team, and more information on its effectiveness is needed. In this study, they will look at the ability of IP-MS to detect key Aab in Bath. Dr Tansley will also use IP-MS to find new AAb. Going forwards, it is believed IP-MS could increase the availability of accurate AAb testing, help find new AAb and lead to new research opportunities.



Bursaries

Building on the recent success of early career researchers **BIRD awarded £5,218.04 for bursaries to attend BSR and EULAR in 2024-2025.**

This is to **encourage health professionals** based in the Royal National Hospital for Rheumatic Diseases (RNHRD) to **attend these key national and international conferences** as part of **BIRD's mission to encourage clinical staff to be research-active** and to maintain the RNHRD's reputation for research excellence.

For the **third consecutive year**, BIRD took a stand at the annual **British Society for Rheumatology Conference in Liverpool** to **showcase its Patient Engagement programme**. This was to promote and network for further patient engagement opportunities.



Thank you so much to BIRD for enabling me to attend. It was an absolute joy to share in several days of learning, networking and personal growth with academic and clinical colleagues, and a definite highlight of my PhD thus far! Rosie Barnett

Many thanks to BIRD for facilitating my attendance at EULAR 2024 in Vienna. It was an enjoyable experience learning from top rheumatology experts and networking with colleagues. I plan to apply the key lessons in my daily practice to enhance patient care. Please keep up the good work. Akpabio Akpabio

Thanks so much for BIRD support to attend my first BSR meeting. It was great to hear from leading clinicians and researchers in the field of AxSpA and axial PsA, and also be able to attend other sessions covering a range of the rheumatology field. Ben Davies

So grateful for your support to be here - so many inspiring and interesting sessions attended, and many yet to come. Thank you. Jade Skeates

BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the **Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education and Research Trust**. The programme was **attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals**.

BIRD provided the administration support including the accreditation and sponsorship where necessary, for educational events reaching **730 healthcare professionals**, a record breaking year.

Each of the **training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust** (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

The Education Programme was led by Dr Andrew Allard, Consultant Rheumatologist, and Fran Staples, Senior Administrator BIRD.

The programme for 2024/25 included the following events:

Two Bath & Bristol Bone Meetings were held in May and November 2024 for consultants and clinical staff.

The South West Axial Spondyloarthritis Group Regional Meeting was held in November 2024 for consultants and clinical staff. This meeting was an opportunity for all healthcare professionals working in the South West and South Coast areas, who have a strong interest in Axial Spondyloarthritis, to meet with their colleagues and discuss potential future collaborative research and quality improvement initiatives.

Two South West CTD & Vasculitis Regional Meetings were held in September 2024 and March 2025 for consultants and clinical staff.

The Primary Care Rheumatology Update Afternoon held in March 2025 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

The Axial Spondyloarthritis for Primary Care Webinar was held in May 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

The Fibromyalgia Update for Primary Care Webinar was held in December 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

Ratings as an average of all meetings
Excellent/good rating for relevance of this meeting to your educational needs **92%**

Excellent/good rating for overall quality of the education offered **100%**

BIRD co-hosted the fourth **Skin@Bath Network Symposium** with **198 participants from 12 countries**. **170** of whom attended in person. The Symposium featured **40 talks over two days**. Given by **prestigious national and international clinicians, healthcare professionals and scientists** as well as **early career researchers, medical trainees and postgraduate students**.



The **Nick Hall Memorial Bursary** continued for this conference, giving bursaries to honour his legacy by financially supporting the participation of **three young researchers and medical trainees** either at postgraduate or early career stages of their career to attend the Skin@Bath Network Symposium. **Applicants were restricted to PhD students, postdoctoral researchers, and medical trainees and applications from less privileged countries are prioritised in the selection stage.**

The Patient and Public Engagement Programme

The Programme vision is to **help more patients to be involved in research and deepen their understanding of Rheumatic Diseases and the latest research and treatment.**

With the twin aims of:

Patients having a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals

Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Over the 2024-2025 period, the Patient Engagement and Involvement (PPIE) programme continued to evolve and develop around patient audience needs. It provides opportunities for patients to connect, learn and share through a flexible and innovative mix of media.



Patient Engagement Activities
Webinars - **Six patient information webinars** were held covering **Axial Spondylarthritis, Psoriatic arthritis and Lupus** with a total attendance of **370 participants** across all webinars. **Feedback was overwhelmingly positive** with attendees expressing **appreciation for the sessions** and suggestions for future topics.



Patient Events - Three patient events were delivered during the year:

- **Professor Tim Spector event** sponsored through Bath Festivals **engaging 103 patients and attended by over 600 people**. This raised **awareness of the charity** with a **full page article** on page three about the charity in the **Bath Chronicle**
- **Seated movement and Dance workshop** with 12 patient attendees
- **Osteoporosis event** with 39 patient attendees

BIRD also hosted an exhibition in the **Bath Central Library** during the month of March. **Celebrating 50 years of working with the Royal National Hospital for Rheumatic Diseases and local arthritis and rheumatology patients;**



Trustees' Annual Report for the year ended 31 March 2025

Videos BIRD now has **24 videos available** on their **YouTube channel**. These continue to be a **valuable resource** with **significant growing viewership**, especially through the Inhealth App used by patients at the RNHRD.



Podcasts - The **podcast programme** remains successful, with **impressive listening figures** that **enable thousands of patients** and their families nationwide to **access information** about a **wide range of rheumatology conditions**.

Patient Research Involvement
The **Patient Research Panel**, consisting of **46 committed volunteers**, provided **feedback on survey design** and **research opportunities** to **academic and clinical researchers** during the year.

A variety of Patient and Public Involvement and Engagement (PPIE) activities were facilitated, including:

- **Virtual Reality motor impairment project**
- **Research Grant Bid (LEAP) for axSpA**
- **Virtual Reality Research in Flare Ups/ axSpA**
- **TULIPS (PsA) project**
- **Wearable technology research in axSpA**
- **Gemini Study (RMD+COPD)**
- **PsA X-Rays Workshop**
- **AxSpa/neurofeedback study**
- **PsA biologics Workshop**
- **Fibromyalgia cognitive issues research**

One researcher commented:

"The research engagement support BIRD provides through the PPE programme has been invaluable for furthering our research into how technology can support patients. Having worked with the team across several projects, they have been incredibly supportive at every stage of the process and helped to ensure the successful delivery through recruitment and engagement with patients which provides important feedback and actionable improvements to our research."

This comment **highlights the value of early-stage PPI support** and the **power of direct patient engagement** aimed at **improving the lives of those living with chronic conditions**.

Awareness raising


The reach of BIRD continued to expand through ongoing investment in social media platforms including Facebook, Instagram and LinkedIn.

Trustees' Annual Report for the year ended 31 March 2025

The charity achieved notable growth with:

- **Steady increase in Facebook followers with higher content interactions (2.7K in 2025 compared to 2.2K previously)**
- **Increased website visits from 4.7K to 7.1K**
- **Growth in Instagram followers from 112 to 179**
- **LinkedIn connections increasing from 109 to 161**

A significant milestone was the **launch of a newly designed website** in November 2024, updating and enhancing **BIRD's digital presence**.



The **BIRD newsletter programme** continued with **nine general public newsletters** and **stakeholder newsletters** sent throughout the year, reaching a **growing audience of 1,302 active contacts** (general public) and **159 stakeholders**.

The **following people and trusts** gave **significant donations and legacies** for which **BIRD is very grateful**, and their names were added to the Benefactors Board, recently moved to the entrance of the Royal National Hospital for Rheumatic Diseases

The Champniss Trust; Erika Wiesenmueller-Potter and Barry Potter; Derek Pitman; Don and Janet Templeton; Medlock Charitable Trust.

Some of the achievements and performance of the charity in terms of public benefit:

The **total amount of grants and bursaries awarded for research** into rheumatic diseases **exceeded £60,000**

730 professionals attended **BIRD training sessions**, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics, **a record breaking year**

85% of patients who attended the **Lupus webinar** **felt they understood their condition** and **would manage their condition better after the webinar**.

46 committed volunteers, provided **feedback on survey design** and **research opportunities** to **academic and clinical researchers** during the year.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Structure, governance and management of
the charity

The governing body is the **Council of Management** made up of 9 trustees. The chair is now Professor Bernie Morley emeritus, Council of Management meets triannually

Three committees report to the Council of Management.

These are the **triannual Finance Committee**, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns Linda Snelus and Bernard Fairhurst; the **biannual Research Committee**, chaired by Professor Bernie Morley emeritus, members are Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr Sarah Skeoch, Dr Paula Smith, Dr Theresa Smith, Frank Sweeting and Dr Sarah Tansley; and the **triannual Education & Engagement Committee**, chaired by Shane O'Reilly, members are Dr Andrew Allard, Patricia Mattinson and Jessie Naish. All committees are supported by relevant contract staff in attendance.

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham B1 2HB

CCLA Investment Management Ltd, COIF Charity Funds, 1 Angel Lane, London EC4R 3AB

Solicitors

Stone King, 13 Queen Square, Bath BA1 2HJ

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath BA1 3RU

Financial review

The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2025 £	2024 £
Net income	(242,427)	115,039
Unrestricted Revenue Funds available for the general purposes of the charity	1,517,547	1,754,967
Designated Revenue Funds	14,843	18,478
Total Unrestricted Funds	1,532,390	1,773,445
Restricted Revenue Funds	16,821	18,193
Total Funds	1,549,211	1,791,638

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

BIRD's reserves policy is to

-hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
-retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £90,000, depending on the quality of applications received and will encourage clinicians to undertake research and early stage career researchers. It will help thousands of patients to understand their disease and treatment better and, with renewed focus, hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

Details of The Independent Examiner

Tom Case
Member of The Institute of Chartered
Accountants in England and Wales 20
Goodwood Way
Cepen Park South Chippenham Wiltshire
SN14 0SY

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements. Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 16 to 37.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the Board of Trustees on 4 July 2025.



Bernie Morley
Chair

I report to the Trustees on my examination of the financial statements of the charitable company on pages 16 to 37 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 23.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider

in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide.

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion


Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
- and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
- accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;
- the financial statements do not accord with those records; or

- the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;
- have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tom Case - Independent Examiner

The Institute of Chartered Accountants in England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire SN14 0SY

This report was signed on 02 October 2025.

**Statement of Financial Activities
for the year ended 31 March 2025**

	SORP Ref	Current Unrestricted Funds	Current Restricted Funds	Current Total Funds	Prior Total Funds
		2025 £	2025 £	2025 £	2024 £
Income & Endowments from:					
Donations & Legacies	A1	6,244	-	6,244	38,464
Charitable activities	A2	55,625	100	55,725	24,625
Investments	A4	42,485	-	42,485	43,797
Total income	A	104,354	100	104,454	106,886
Expenditure on:					
Charitable activities	B2	240,127	352	240,479	238,680
Total expenditure	B	240,127	352	240,479	238,680
Net gains/(losses) on investment	B4	(106,402)	-	(106,402)	246,833
Net income for the year		(242,175)	(252)	(242,427)	115,039
Transfers between funds	C	1120	(1,120)	-	-
Net income after transfers	A-B-C	(241,055)	(1,372)	(242,427)	115,039
Net movement in funds		(241,055)	(1,372)	(242,427)	115,039
Reconciliation of funds:-					
	E				
Total funds brought forward		1,773,445	18,193	1,791,638	1,676,599
Total funds carried forward		1,532,390	16,821	1,549,211	1,791,638

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.
All activities derive from continuing operations

The notes attached on pages 23 to 37 form an integral part of these accounts.

**Statement of Financial Activities
for the year ended 31 March 2025**

Analysis of prior year total funds as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Income & Endowments from:				
Donations & Legacies	A1	38,464	-	38,464
Charitable activities	A2	24,550	75	24,625
Investments	A4	43,797	-	43,797
Total income	A	106,811	75	106,886
Expenditure on:				
Charitable activities	B2	238,208	472	238,680
Total expenditure	B	238,208	472	238,680
Net gains/(losses) on investments	B4	246,833	-	246,833
Net income for the year		115,436	(397)	115,039
Transfers between funds	C	89	(89)	-
Net income after transfers		115,525	(486)	115,039
Net movement in funds		115,525	(486)	115,039
Reconciliation of funds:-				
	E			
Total funds brought forward		1,657,920	18,679	1,676,599
Total funds carried forward		1,773,445	18,193	1,791,638

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 23 to 47 form an integral part of these accounts.

Statement of Total Recognised Gains and Losses for the year ended 31 March 2025

	2025 £	2024 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(136,025)	(131,794)
	-	-
Income from operations before tax in the Statement of Financial Activities	(136,025)	(131,794)
Unrealised (losses)/gains on investments	(106,402)	246,833
Net Movement in funds before taxation	(242,427)	115,039
Funds generated in the year as shown on Statement of Financial Activities	(242,427)	115,039

Resources applied in the year ended 31 March 2025 towards fixed assets for
Charity use

	2025 £	2024 £
Funds generated in the year as detailed in the SOFA	(242,427)	115,039
Resources applied on functional fixed assets	(300)	(1,549)
Net resources available to fund charitable activities	(242,727)	113,490

Movements in revenue and capital funds for the year ended 31 March 2025

Revenue accumulated funds	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Funds 2024 £
Accumulated funds brought forward	1,773,445	18,193	1,791,638	1,676,599
Recognised gains and losses before transfers	(242,175)	(252)	(242,427)	115,039
	1,531,270	17,941	1,549,211	1,791,638
(From)/To unrestricted revenue funds	1,120	(1,120)	-	-
Closing revenue funds	1,532,390	16,821	1,549,211	1,791,638

Designated revenue funds included within the unrestricted funds above

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Funds 2024 £
At 1 April			18,478	26,886
Transfer (to)/from revenue accumulated funds			(3,635)	(8,408)
At 31 March			14,843	18,478
The purposes for which these funds have been designated are described in Note 20 to the accounts.				
Revenue accumulated funds	1,517,547	16,821	1,534,368	1,773,160
Revenue designated funds	14,843	-	14,843	18,478
Total funds	1,532,390	16,821	1,549,211	1,791,638

Statement of Financial Activities for the year ended 31 March 2025

Income and Expenditure Account for the year ended 31 March 2025 as required by the Companies Act 2006

	2025 £	2024 £
Income		
Income from operations	61,969	63,089
Investment income		
Income from investments, other than interest receivables	42,485	43,797
Gross income in the year before exceptional items	104,454	106,886
Gross income in the year including exceptional items	104,454	106,886
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	239,370	237,788
Depreciation and amortisation	635	430
Governance costs	474	462
Total expenditure in the year	240,479	238,680
Net income before tax in the financial year	(136,025)	(131,794)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(136,025)	(131,794)
Retained surplus for the financial year	(136,025)	(131,794)

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 23 to 37 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2025

Balance Sheet as at 31 March 2025

	SORP Note Ref	2025 £	2024 £
Fixed assets A			
Tangible assets	9 A2	1,451	1,786
Investments held as fixed assets	10 A4	1,615,394	1,871,796
Total fixed assets		1,616,845	1,873,582
Current assets	B		
Debtors	12 B2	6,207	5,774
Cash at bank and in hand	B4	55,499	44,602
Total current assets		61,706	50,376
Creditors: amounts falling due within one year	13 C1	(129,340)	(132,320)
Net current assets		(67,634)	(81,944)
The total net assets of the charity		1,549,211	1,791,638
The total net assets of the charity are funded by the funds of the charity, as follows:-			
Restricted funds			
Restricted Revenue Funds	17 D2	16,821	18,193
Unrestricted Funds			
Unrestricted Revenue Funds	17 D3	1,517,547	1,754,967
Designated Funds			
Designated Revenue Funds	17 D3	14,843	18,478
Total charity funds		1,549,211	1,791,638

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



James Sherwin
Trustee and Chair of the Finance Committee

Approved by the Board of Trustees on
4 July 2025

The notes attached on pages 23 to 37 form an integral part of these accounts.

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material

uncertainties about the charity's ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition. Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery 20 % reducing balance

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.

There are no endowment funds.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Significance of financial instruments to the charity's position

There are no significant implications of financial instruments to the charity's financial position or performance.

5 Net surplus before tax in the financial year

	2025	2024
	£	£
The net surplus before tax in the financial year is stated after charging:-		
Depreciation of owned fixed assets	635	430

6 Investment gains

Unrealised gains /(losses) and writing down of carrying values

	Current year Unrestricted Funds 2025	Current year Restricted Funds 2025	Current year Total Funds 2025	Prior Year Total Funds 2024
Listed investments - Unrealised	(106,402)	-	(106,402)	246,833
Total unrealised gains/(losses) etc	(106,402)	-	(106,402)	246,833
Total realised and unrealised gains	106,402	-	(106,402)	246,833

All the gains and losses in the prior year was unrestricted.
Unrealised gains /(losses) and writing down of carrying values

Listed investments - Unrealised	246,833	-	246,833
Total unrealised gains/(losses) etc	246,833	-	246,833
Total realised and unrealised gains	246,833	-	246,833

7 Staff costs and emoluments

Labour costs	2025 £	2024 £
Gross salaries, labour and related costs	126,781	133,060
	126,781	133,060

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

9 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2024	-	13,489	-	13,489
Additions	-	300	-	300
At 31 March 2025	-	13,789	-	13,789
Depreciation				
At 1 April 2024	-	11,703	-	11,703
Charge for the year	-	635	-	635
At 31 March 2025	-	12,338	-	12,338
Net book value				
At 31 March 2025	-	1,451	-	1,451
At 31 March 2024	-	1,786	-	1,786

10 Investments held as fixed assets

	Investments in subsidiaries	Listed investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2024	2	1,871,794	-	1,871,796
Revaluation at 31 March 2025	-	(106,402)	-	(106,402)
Disposals	-	(150,000)	-	(150,000)
At 31 March 2025	2	1,615,392	-	1,615,394
Analysis between fair value and historical cost				
Investments as above held at fair value	2	1,615,392	-	1,615,394

11 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the ten years ending 31st March 2025.

A summary of the unaudited financial statements of the subsidiary is :-

	2025 £	2024 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)

Profit and Loss

<i>Net profit for the year before tax</i>	-	-
<i>Net profit for the year after tax and Gift Aid</i>	-	-

Funds retained within charitable subsidiaries	2025 £	2024 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are	-	-
	-	-

12 Debtors

	2025 £	2024 £
Trade debtors	5,946	5,513
Prepayments and accrued income	261	261
	6,207	5,774

13 Creditors: amounts falling due within one year

	2025 £	2024 £
Trade creditors	19,874	42,542
Accruals	13,200	9,900
Other creditors	96,266	79,878
	129,340	132,320

14 Income and Expenditure account summary

	2025 £	2024 £
At 1 April 2024	1,544,805	1,676,599
Transfers in for the year	-	-
At 1 April 2024	1,544,805	1,676,599
Surplus after tax for the year	(136,025)	(131,794)
At 31 March 2025	1,408,780	1,544,805

15 No related party transactions

There were no transactions with related parties in the year.

16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2025	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	1,451	-	-	1,451
Investments at valuation:-				
Fixed asset investments	1,615,394	-	-	1,615,394
Current Assets	26,407	18,478	16,821	61,706
Current Liabilities	(130,460)	-	-	(130,460)
	1,512,792	18,478	16,821	1,548,091
At 1 April 2024	Unrestricted funds £	Designated funds £	Restricted funds £	Total Funds £
Tangible Fixed Assets	1,786	-	-	£1,786
Investments at valuation:-				
Fixed asset investments	1,871,796	-	-	1,871,796
Current Assets	13,705	18,478	18,193	50,376
Current Liabilities	(132,320)	-	-	(132,320)
	1,754,967	18,478	18,193	1,791,638

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2024 £	Movement in funds in 2025 £ see note 18	Transfers between funds in 2025 £ see note 19	Funds carried forward to 2026 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,754,967	(242,175)	4,755	1,517,547
Designated Revenue Funds	18,478	-	(3,635)	14,843
Total unrestricted and designated funds	1,773,445	(242,175)	1,120	1,532,390
<i>Restricted funds:-</i>				
Restricted - CRPS Conference	1,120	-	(1,120)	-
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Metabolic Bone Disease	2,928	(252)	-	2,676
Total restricted funds	18,193	(252)	(1,120)	16,821
Total charity funds	1,791,638	(242,427)	-	1,549,211

18 Analysis of movements in funds over the year as shown in Note 17

	Income 2025 £	Expenditure 2025 £	Other Gains & Losses 2025 £	Movement in funds 2025 £
<i>Unrestricted and designated funds:-</i>				
Unrestricted Revenue Funds	104,354	(240,127)	(106,402)	(242,175)
<i>Restricted funds:-</i>				
Restricted - Metabolic Bone Disease	100	(352)	-	(252)
	104,454	(240,479)	(106,402)	(242,427)

19 Details of transfers between

The transfers shown in note 17 above are:-

	2025 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	4,755
To/(from) Designated Revenue Funds	(3,635)
To/(from) Restricted Revenue Funds	(1,120)
Net transfers	-

20 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and, subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds Funds specific for this purpose.

Restricted funds:-

Restricted Revenue Funds Funds specific for this purpose.

21 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

22 Donations, Grants and Legacies

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Donations and gifts from individuals				
Donations	6,244	-	6,244	38,462
Total donations and gifts from individuals	6,244	-	6,244	38,462

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Legacies receivable				
Legacies receivable	-	-	-	2
Total legacies receivable	-	-	-	2

Total Donations, Grants and Legacies

Total Donations, Grants and Legacies	A1	6,244	-	6,244	38,464
---	-----------	--------------	----------	--------------	---------------

23 Income from charitable activities - Trading Activities

Current year	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Primary purpose and ancillary trading				
Education income	34,358	100	34,458	1,998
Other and recharged income	-	-	-	105
Service charges - BGPRT	16,685	-	16,685	17,558
Service charges - BRIT PACT	4,582	-	4,582	4,964
Total Primary purpose and ancillary trading	55,625	100	55,725	24,625

Not all the trading activities in the prior year were unrestricted

Prior year	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Primary purpose and ancillary trading			
Other and recharged income	30	75	105
Total Primary purpose and ancillary trading	24,550	75	24,625

24 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total income from charitable trading	55,625	100	55,725	24,625
Total from charitable activities A2	55,625	100	55,725	24,625

Not all the income in the prior year was unrestricted.

Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Total income from charitable trading	24,550	75	24,625
Income from funders	-	-	-
	24,550	75	24,625

25 Investment income

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Dividend Income	42,485	-	42,485	43,797
Total investment income A4	42,485	-	42,485	43,797

26 Expenditure on charitable activities - Direct spending

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Labour costs - charitable activities	126,781	-	126,781	133,060
Education costs	39,569	352	39,921	7,741
PPE Project costs	-	-	-	2,344
Total direct spending B2a	166,350	352	66,702	143,145

Not all the expenditure in the prior year was unrestricted.

27 Expenditure on charitable activities- Grant funding of activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Grants made to individuals	32,865	-	32,865	63,776
Total grantmaking costs B2c	32,865	-	32,865	63,776

28 Support costs for charitable activities

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Premises Expenses				
Rent	3,300	-	3,300	3,300
Administrative overheads				
Telephone, fax and internet	1,056	-	1,056	1,034
Stationery and printing	645	-	645	1,151
Marketing and promotion	22,427	-	22,427	14,926
Registration and licensing	3,025	-	3,025	1,622
IT support costs	1,630	-	1,630	2,380
Recharged expenses	-	-	-	72
Insurance	617	-	617	547
Trustees costs	296	-	296	177
Hospitality	268	-	268	472
Travel	1,007	-	1,007	20
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	3,612	-	3,612	4,033
Other legal and professional	1,774	-	1,774	1,017
Financial costs				
Bank charges	146	-	146	116
Depreciation	635	-	635	430
Total support costs	40,438	-	40,438	31,297
<i>Prior year</i>	Current Year Unrestricted Funds 2024 £	Current Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £	
Recharged expenses	(400)	472	72	
Total support costs - Prior Year	30,825	472	31,297	

29 Other Expenditure - Governance costs

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Prior Year Total Funds 2025 £	Total Funds 2024 £
Independent Examiner's fees	474	-	474	462
Total Governance costs	474	-	474	462

All the expenditure in the prior year was unrestricted.

30 Total Charitable expenditure

<i>Current year</i>	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total direct spending	166,350	352	166,702	143,145
Total grantmaking costs	32,865	-	32,865	63,776
Total support costs	40,438	-	40,438	31,297
Total Governance costs	474	-	474	462
Total charitable expenditure B2	240,127	352	240,479	238,680
<i>Prior year</i>	Current Year Unrestricted Funds 2024 £	Current Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £	
Total direct spending	143,145	-	143,145	
Total grantmaking costs	63,776	-	63,776	
Total support costs	30,825	472	31,297	
Total Governance costs	462	-	462	
Total charitable expenditure B2	238,208	472	238,680	



CELEBRATING 50 YEARS

Bath Institute for Rheumatic Diseases
Arthritis | Research | Education

Company Registration
Number 02908933
Charity Registration
Number 1040650

Accounts



Supporting arthritis research, education
and patient engagement



**ANNUAL
REPORT
AND
ACCOUNTS**
31 March 2024

**Company Registration
Number 02908933
Charity Registration
Number 1040650**



Contents	Page
Charity information	1
Trustees' Annual Report	2
Statement of directors' responsibilities	12
Independent Examiner Report	14
Funds Statements:-	
Statement of Financial Activities	16
Prior Year statement	17
Statement of total recognised gains and losses	18
Income and Expenditure account	19
Balance sheet	20
Notes to the accounts	22



Charity information

The Trustees present their Report and Accounts for the year ended 31 March 2024, which also comprises the Directors' Report required by the Companies Act 2006.

The charity name

The legal name of the charity is:- Bath Institute for Rheumatic Diseases. The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650. The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Department D1
Wolfson Building, Royal United Hospital Bath,
BA1 3NG
Telephone 01225 336363

BIRD@birdbath.org.uk www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office for the period covered by the report:

Chris Johns
Dr Amanda Mackenzie
Prof Neil McHugh
Prof Bernie Morley emeritus - **Chair**
Shane O'Reilly
Prof Raj Sengupta
Jim Sherwin
Linda Snelus
Dr William Tillet

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Objects and activities of the charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Strategy

We continue to follow our new strategy with the central purpose of balancing reliance on investment performance over the long term with more grant and donor fundraising, which in turn requires a raised profile and clearer articulation of impact.

A recent stakeholders survey highlighted the progress we have made with comments such as **"BIRD is now more outgoing and focused on engagement and education of staff and patients"** and **"overall I think that the organisation now reaches far more people than in the past and the number research grants given has increased"**.

Highlights

- **Shortlisted for Charity of the Year in the South West Business Awards**
- **Reaching the 20,000 milestone in listens to BIRD podcasts for patients**
- **BIRD attending the British Society of Rheumatologists conference for the second time to highlight our work**
- **BIRD organising the second Research Showcase event in Bath**
- **BIRD producing six new videos for use in the reception area of the Royal National Hospital for Rheumatic Diseases**
- **BIRD being placed on the Chancellor's Roll of Honour at the University of Bath (see below)**



We finish the financial year with £1,791,638 in funds, up from £1,676,599 at the same point last year, reflecting good growth in BIRD's investment funds since income totalled £106,886 but expenditure £238,682. In total BIRD awarded £66,406 in grants and bursaries to clinician researchers and early career researchers and spent £59,054 on patient and public engagement.

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Grants awarded for research

BIRD funds research projects in rheumatic diseases which:

- **Help to promote and advance medical knowledge**
- **Improve treatments for patients**
- **Encourage collaboration between clinicians and research scientists**
- **Supports the next generation of researchers into bone and joint diseases**

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

It aims to promote and advance medical science, pump-priming research, help researchers in the early stages of their careers, help clinicians to be research active, encourage collaborations between clinicians and research scientists, and ensure patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded over 26 projects, with over 600 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

In total, £63,551 for research was awarded

£19,950 to Dr Jessica Ellis for a project about the Utility of a novel imaging biomarker for the identification of excess cardiovascular risk in auto-immune rheumatic diseases.

We hope this project will improve the identification of cardiovascular disease in rheumatology patients. It will use existing CT scans from lupus and scleroderma patients, and measure inflammation on these scans. This project will then see whether it can identify increased cardiovascular risk using existing tools. It will also use a large national database of scans, to see whether rheumatology patients are more likely to have this inflammation.

£19,953 to Dr Amanda Mackenzie for a project promoting the regression of angiogenesis in the pathology of rheumatoid arthritis. Rheumatoid arthritis is a common disease, affecting more than 400,000 in the UK. Blood vessels grow into joints during the progression of the disease. This growth makes the damaging inflammation worse and increases joint pain. This project aims to improve treatments for patients with rheumatoid arthritis and promote collaboration between clinical and research scientists.

£2720 to Fionnula McMorow For knowledge exchange of IP-MS method at KU Leuven. As part of a PhD this project involves using and adapting highly specialised laboratory techniques to try and find new autoantibodies in the blood of children with rare rheumatic diseases called myositis and systemic sclerosis,

Research Collaboration
Encouraging Partner Efficient
Patient Interaction Patient Engagement
WHAT DO Innovative Research active
OUR STAKEHOLDERS Friendly
Podcasts **THINK OF BIRD?**
Supports clinicians and patients
Patient oriented organisation
Great Resources Charity

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

£20,000 to Dr Joseph Page for assessing the Vascular Endothelium in Systemic sclerosis associated Pulmonary hypertension to improve Early and Rapid diagnosis (VESPER)

Pulmonary arterial hypertension (PAH) and progressive fibrotic interstitial lung disease (ILD) are common and sadly fatal complications of Systemic Sclerosis. The study will invite patients with and without systemic sclerosis to provide a blood test. The researchers will compare the results between patients with and without systemic sclerosis. It will also look to see whether these tests match with right heart catheterisation results in patients who have this test done as part of their routine care. If we can improve our understanding of blood vessel damage in systemic sclerosis, it may help us to predict which patients are more at risk of developing PAH, and commence timely treatment. It may help provide more accurate non-invasive tests to detect PAH.

£928 to the RNHRD Research Nurses for a Laptop

Bursaries

Building on the recent success of early career researchers BIRD awarded £2755 for bursaries to attend BSR and EULAR, and the World Congress on Osteoporosis in early 2024.

This is to encourage health professionals based in the Royal National Hospital for Rheumatic Diseases (RNHRD) to attend these key national and international conferences as part of BIRD's mission is to encourage clinical staff to be research-active and to maintain the RNHRD's reputation for research excellence.



"The British Society for Rheumatology (BSR) conference, is a key event in my work calendar. Every year I meet new people and develop contacts with colleagues around the UK. Lots of action points and things for us to review and develop further in our service here in Rheumatology Therapies".

"Thanks so much for BIRD support to attend my first BSR meeting. It was great to hear from leading clinicians and researchers in the field of AxSpA and axial PsA, and also be able to attend other sessions covering a range of the rheumatology field. Quite mind-blowing at times".

"My experience at BSR was fabulous. I was able to discuss complex cases with my colleagues and also saw many interesting educational abstracts. This gave me further ideas on how to innovate our system but also enabled me to enhance my research work".

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

For the second time BIRD took a stand at the annual British Society for Rheumatology Conference in Manchester to showcase the Patient Engagement programme. This was to promote and network for further patient engagement opportunities.

BIRD led and organised the RNHRD's second Research Showcase Event at the Bath Royal Literary and Scientific Institute in March 2024 together with Royal United Hospital Bath, and the University of Bath.

Five Consultants and early career researchers from the RNHRD gave talks on their research and showed 10 research posters for 60 members of the general public. The feedback was again very positive and BIRD plan to make the Research Showcase an annual event.



"All of the talks were engaging. It is wonderful to listen to our doctors so full of passion for their specialism and wanting to provide the best for their patients".

"I found the talks all very informative, very interesting and very beautifully presented by the professionals. I am very grateful to have attended and would love to come to other similar events. I hope that there will be more".

"We really enjoyed the speakers and their enthusiasm into their specialist research. It was wonderful to see their passion and desire to find out more around their specialism and their desire to pass on their findings for those in their care now and in the future".



Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education and Research Trust. The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration support including the accreditation and sponsorship where necessary, for **educational events reaching 415 healthcare professionals**. Each of the training sessions was **approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust** (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

The programme for 2023/24 included the following events:

One Rheumatology Research @ Bath meeting was held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time.

Two Bath & Bristol Bone meetings were held in May and November 2023 for consultants and clinical staff.

The South West Axial Spondyloarthritis Group was held in November 2023 for consultants and clinical staff.

Two South West CTD & Vasculitis meetings were held in March & September 2023 for consultants and clinical staff.

Two Primary Care Rheumatology Update afternoons were held in April 2023 and March 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

Knowledge Exchange with Stoke UHNM NHS Trust & RNHRD – BIRD provided the organisation and admin support for the Stoke visit to Bath. Over the two-day event each Trust shared their practices and procedures for the Management of Spondyloarthritis.

Qualitative feedback collected from some of the sessions showed that participants rated talks either **'excellent'** or **'good'** with most comments finding the training "helpful" and a useful update;

"The hybrid option for meetings is really valuable and great to see so many attendees online. Great selection of speakers at these events, with fantastic external speakers. Good to see some younger investigators given chance to present and raise their profiles within the region."

"These are always great meetings - all presentations excellent and very useful discussion. The meeting was very well organised and chaired."

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

The Patient and Public Engagement Programme

The Programme vision is to **help more patients to be involved in research and deepen their understanding of Rheumatic Diseases**, the latest research and treatment. With the twin aims of:

1. Patients have a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals

2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke and supported by Fran Carroll, **the programme has continuously evolved and developed around patient audience needs**. It provides **opportunities** for them to **connect, learn and share** through a flexible and innovative mix of media.

Podcasts - covering a range of rheumatology conditions, these **now reach thousands of patients and their families**, across the country (and beyond) which we promote heavily on social media.



Over the year Mel Brooke produced another **10 new podcasts** bringing the **library to 58** and achieving an amazing **total of 23,559 listens**.

New topics covered were **Gout, Myositis, new BSR guidelines, Psoriatic Arthritis (PsA), updated NICE guidelines on Osteo Arthritis Nutrition, Pain and Mental Health**

Webinars - were developed, providing **live events online** that **give patients access to consultants** and experts' presentations and the opportunity to ask questions. **577 patients attended six webinars** on Axial Spondyloarthritis, PsA and Osteoporosis.



"A very useful webinar covering a great deal of research explained in a digestible way."

"I've learnt some things today which have completely changed my view on my disease activity and care alongside that."

"So grateful for these webinars, the knowledge shared, and opportunity to ask questions."

100% of patients who attended the Osteoporosis webinar would recommend others to attend.

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Research - patients tell us they are keen to 'give back' and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. **Over 188 patients were involved in research during the year.**

Patient Research Panel – 28 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year

Some highlights of the work involving patients in research over the last year include

- *helping the RUH Research Database Team to engage patients to help test an online survey designed to support the Rheumatology Advice Line.*
- *supporting a researcher to share a call for people to participate in a Fibromyalgia Focus Group*
- *guiding the patient research panel to lay review a Patient Information Leaflet for a new tissue bank relating to Systemic Autoimmune Rheumatic Diseases (SARDs)*
- *helping a researcher find participants for a PsA workshop in biologics, set up and co-host the online evening workshop, help capture and summarise the qualitative data input.*
- *helping to share a survey to gather patient opinions and, later, help again to find participants to attend a workshop (research to develop the concept for a new tool to support hand exercise and self-manage medications in RA)*
- *helping the Rheumatology Research Team at the RUH to find volunteers to participate in a research study day in PsA*
- *helping a historical writer find people to share lived experience of Lupus for research for their book. WW*


- *helping share an opportunity for people with PsA to participate in a project aimed at helping improve the patient and public engagement in clinical trials.*
- *helping to find patients to participate in workshops about PIFU (Patient Initiated Follow Up)*
- *helping to review patient information documents for an observational study on use of a medication in axSpA and PsA (through the Patient Research Panel)*
- *helping a researcher shape the questions for a research survey in fatigue and exercise in axSpA and, later, share it with the BIRD patient network to gather patient insights.*

Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook, Instagram, X and LinkedIn, with over **334,000 people getting the opportunity to see a BIRD advertisement for podcasts**. BIRD's subscriber database grew by **34%** across Twitter, Facebook, Mailchimp and LinkedIn.

Particular success was achieved in **celebrating the 20,000 listens to podcasts** milestone, achieving good coverage in local press and BBC radio. This led to BIRD being nominated in the South West Business awards as Charity of the year.

BIRD also produced **six information videos to be used in the reception at the RNHRD**



Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

–these covered various topics including an introduction to the RNHRD, Biologics and a short introduction to the research department's work.

BIRD was also delighted to be **placed on the Chancellors Roll of Honour at the University of Bath**, this recognises the support BIRD has given the University over the years.

Effort spent in seeking to attract **grants** from pharmaceutical companies for the **Patient Engagement programme** was rewarded with **£22,000 in grants and sponsorship from Eli Lilly and Company and UCB**. This was largely due to the **excellent performance of the podcasts** and advertising them widely on social media, which attracted thousands of listeners.

The **following people and trusts gave significant donations and legacies for which BIRD is very grateful**, and their names were **added to the Benefactors Board**, recently moved to the entrance of the Royal National Hospital for Rheumatic Diseases

Erika Wiesenmueller-Potter and Barry Potter
Mary Dixon
Medlock Charitable Trust
Hospital Saturday Fund
Renishaw

Many others made donations to BIRD over the year, often after reading news or research and developments in BIRD's newsletter. **Thank you to all for the vital support.**



The main achievements and performance of the charity in terms of public benefit

The **total amount of grants and bursaries** awarded for research into rheumatic diseases was **£66,406**

415 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

100% of patients who attended the Osteoporosis webinar **would recommend others to attend future webinars**

15 opportunities to participate in research, were offered to patients, **26 members** of the patient research panel **responded to 5 new research opportunities**.

90% of the 60 attendees to the Research Showcase said they were **more likely to get involved in research**.

188 Patients involved in research

Awareness raising continued to grow through **advertising, e-newsletter engagement** and stakeholder relations with the University and the Hospital.

34% growth in subscribers

BIRD recruited new committee members to the finance and research committees.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.



Structure, governance and management of the charity

The governing body is the Council of Management made up of 9 trustees. The chair is now Professor Bernie Morley emeritus, the Council of Management meets triannually.

Three committees report to the Council of Management.

There are the triannual **Finance Committee**, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns, Linda Snelus and new member Bernard Fairhurst; the biannual **Research Committee**, chaired by Professor Bernie Morley emeritus, members are Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr Sarah Skeoch, Dr Paula Smith-resigned and has been replaced by Dr Abbie Jordan, Dr Theresa Smith, Frank Sweeting and Dr Sarah Tansley; and the triannual **Education & Engagement Committee**, chaired by Shane O'Reilly, members are Dr Andrew Allard, Patricia Mattinson and Jessie Naish. All committees are supported by relevant contract staff in attendance.

	2024 £	2023 £
Net income	115,039	(142,906)
Unrestricted Revenue Funds available for the general purposes of the charity	1,754,967	1,631,034
Designated Revenue Funds	18,478	26,886
Total Unrestricted Funds	1,773,445	1,657,920
Restricted Revenue Funds	18,193	18,679
Total Funds	1,791,638	1,676,599

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.



BIRD's reserves policy is to

- hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised.

Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received. It will encourage clinicians to undertake research and early stage career researchers with their development through enhanced numbers of bursaries for conference attendance.

BIRD will continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers to work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

As part of its 50th Anniversary in 2025 BIRD will maximise engagement with the public, patients and stakeholders.



Details of The Independent Examiner

Tom Case
Member of The Institute of Chartered
Accountants in England and Wales
20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions. The financial statements are set out on pages 16 to 35.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 20 September 2024.

Professor Bernie Morley emeritus
Chair



I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 34 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 21.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider



in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide.

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
- and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
- accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;
- the financial statements do not accord with those records; or

- the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;
- have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-

Tom Case - Independent Examiner

The Institute of Chartered Accountants in
England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire SN14 0SY

This report was signed on 20 September 2024.

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

	SORP Ref	Current Unrestricted Funds	Current Restricted Funds	Current Total Funds	Prior Total Funds
		2024 £	2024 £	2024 £	2023 £
Income & Endowments from:					
Donations & Legacies	A1	38,464	-	38,464	52,340
Charitable activities	A2	24,550	75	24,625	66,645
Investments	A4	43,797	-	43,797	44,462
Total income	A	106,811	75	106,886	163,447
Expenditure on:					
Charitable activities	B2	238,208	472	238,680	244,037
Total expenditure	B	238,208	472	238,680	244,037
Net gains/(losses) on investments	B4	246,833	-	246,833	(62,316)
Net income for the year		115,436	(397)	115,039	(142,906)
Transfers between funds	C	89	(89)	-	-
Net income after transfers	A-B-C	115,525	(486)	115,039	(142,906)
Net movement in funds		115,525	(486)	115,039	(142,906)
Reconciliation of funds:-					
	E				
Total funds brought forward		1,657,920	18,679	1,676,599	1,819,505
Total funds carried forward		1,773,445	18,193	1,791,638	1,676,599

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.

All activities derive from continuing operations

The notes attached on pages 22 to 35 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Analysis of prior year total funds as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Income & Endowments from:				
Donations & Legacies	A1	52,340	-	52,340
Charitable activities	A2	66,495	150	66,645
Other trading activities	A3	-	-	-
Investments	A4	44,462	-	44,462
Other	A5	-	-	-
Total income	A	163,297	150	163,447
Expenditure on:				
Raising funds	B1	-	-	-
Charitable activities	B2	243,443	594	244,037
Other	B3	-	-	-
Tax on surplus on ordinary activities	B3	-	-	-
Other taxation	B3	-	-	-
Total expenditure	B	243,443	594	244,037
Net gains/(losses) on investments	B4	(62,316)	-	(62,316)
Net income for the year		(142,462)	(444)	(142,906)
Transfers between funds	C	2,085	(2,085)	-
Net income after transfers		(140,377)	(2,529)	(142,906)
Net movement in funds		(140,377)	(2,529)	(142,906)
Reconciliation of funds:-				
	E			
Total funds brought forward		1,799,804	19,701	1,819,505
Total funds carried forward		1,659,427	17,172	1,676,599

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 22 to 35 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Statement of Total Recognised Gains and Losses for the year ended 31 March 2024

	2024 £	2023 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(131,794)	(80,590)
Income from operations before tax in the Statement of Financial Activities	(131,794)	(80,590)
Realised (losses)/gains on investments	-	(710)
Surplus as shown in the Income and Expenditure account	(131,794)	(81,300)
Unrealised (losses)/gains on investments	246,833	(61,606)
Net Movement in funds before taxation	115,039	(142,906)
Funds generated in the year as shown on Statement of Financial Activities	115,039	(142,906)

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006

	2024 £	2023 £
Income		
Income from operations	63,089	118,985
Realised gains/(losses) on investments	-	(710)
Investment income		
Income from investments, other than interest receivable	43,797	44,462
Gross income in the year before exceptional items	106,886	162,737
Gross income in the year including exceptional items	106,886	162,737
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	237,788	243,311
Depreciation and amortisation	430	276
Governance costs	462	450
Total expenditure in the year	238,680	244,037
Net income before tax in the financial year	(131,794)	(81,300)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(131,794)	(81,300)
Retained surplus for the financial year	(131,794)	(81,300)

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 21 to 34 form an integral part of these accounts.

Balance Sheet as at 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Balance Sheet as at 31 March 2024

	Note	SORP Ref	2024 £	2023 £
Fixed assets	A			
Tangible assets	9	A2	1,786	667
Investments held as fixed assets	10	A4	1,871,796	1,674,963
Total fixed assets			1,873,582	1,675,630
Current assets		B		
Debtors	12	B2	5,774	9,628
Cash at bank and in hand		B4	44,602	48,995
Total current assets			50,376	58,623
Creditors: amounts falling due within one year	13	C1	(132,320)	(57,654)
Net current assets			(81,944)	969
The total net assets of the charity			1,791,638	1,676,599
The total net assets of the charity are funded by the funds of the charity, as follows:-				
Restricted funds				
Restricted Revenue Funds	17	D2	18,193	18,679
Unrestricted Funds				
Unrestricted Revenue Funds	17	D3	1,754,967	1,631,034
Designated Funds				
Designated Revenue Funds	17	D3	18,478	26,886
Total charity funds			1,791,638	1,676,599

The notes attached on pages 22 to 35 form an integral part of these accounts.

Balance Sheet as at 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

James Sherwin
Trustee and Chair of the Finance Committee
Approved by the board of trustees on
20 September 2024



1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), effective January 2016, and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainties about the charity's ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only



when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the



financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	20 % reducing balance
---------------------	-----------------------

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in

accordance with the guidance given in the SORP.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.

There are no endowment funds.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.



3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Significance of financial instruments to the charity's position

There are no significant implications of financial instruments to the charity's financial position or performance.

5 Net surplus before tax in the financial year

The net surplus before tax in the financial year is stated after charging:-

Depreciation of owned fixed assets:	2024	2023
	£	£
	£430	£ 276



6 Investment gains

	Current year Unrestricted Funds 2024	Current year Restricted Funds 2024	Current year Total Funds 2024	Prior Year Total Funds 2024
Realised gains/(losses)				
Listed investments	-	-	-	(710)
Unrealised gains /(losses) and writing down of carrying values				
Listed investments - Unrealised	246,833	-	246,833	(61,606)
Total unrealised gains/(losses) etc	246,833	-	246,833	(61,606)
Total realised and unrealised gains	246,833	-	246,833	(62,316)

All the gains and losses in the prior year was unrestricted.

Prior year

	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Realised gains/(losses)			
Listed investments	(710)	-	(710)
Total realised gains/(losses)	(710)	-	(710)
Unrealised gains /(losses) and writing down of carrying values			
Listed investments - Unrealised	(61,606)	-	(61,606)
Total unrealised gains/(losses) etc	(61,606)	-	(61,606)
Total realised and unrealised gains	(62,316)	-	(62,316)



7 Staff costs and emoluments

<i>Labour costs</i>	2024 £	2023 £
Gross salaries, labour and related costs	133,060	119,611
	133,060	119,611

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

9 Tangible fixed assets

<i>Current Year</i>	Plant & Machinery £	Motor Vehicles £	Total £
Cost			
At 1 April 2023	11,940	-	11,940
Additions	1,549	-	1,549
At 31 March 2024	13,489	-	13,489
Depreciation			
At 1 April 2023	11,273	-	11,273
Charge for the year	430	-	430
At 31 March 2024	11,703	-	11,703
Net book value			
At 31 March 2024	1,786	-	1,786
At 31 March 2023	667	-	667

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

10 Investments held as fixed assets

	Investments in subsidiaries	Listed Investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2023	2	1,674,961	-	1,674,963
Revaluation at 31 March 2024	-	246,833	-	246,833
Disposals	-	(50,000)	-	(50,000)
At 31 March 2024	2	1,871,794	-	1,871,796

11 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the nine years ending 31st March 2024.

A summary of the unaudited financial statements of the subsidiary is :-

	2024 £	2023 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)

Profit and Loss

Net profit for the year before tax	-	-
Net profit for the year after tax and Gift Aid	-	-

Funds retained within charitable subsidiaries

	2024 £	2023 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	-	-

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

12 Debtors

	2024 £	2023 £
Trade Debtors	5,513	8,767
Payments and accrued income	261	861
	5,774	9,628

13 Creditors: amounts falling due within one year

	2024 £	2023 £
Trade creditors	42,542	14,325
Accruals	9,900	6,600
Other creditors	79,878	36,729
	132,320	57,654

14 Income and Expenditure account summary

	2024 £	2023 £
At 1 April 2023	1,738,205	1,819,505
Surplus after tax for the year	(131,794)	(81,300)
At 31 March 2024	1,606,411	1,738,205

15 No related party transactions

There were no transactions with related parties in the year.

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2024	Unrestricted Funds £	Designated Funds £	Restricted Funds £	Total Funds £
Tangible Fixed Assets	1,786	-	-	1,786
Investments at valuation:-				
<i>Fixed asset investments</i>	1,871,796	-	-	1,871,796
Current Assets	13,705	18,478	18,193	50,376
Current Liabilities	(132,320)	-	-	(132,320)
	1,754,967	18,478	18,193	1,791,638
At 1 April 2023	Unrestricted Funds £	Designated Funds £	Restricted Funds £	Total Funds £
Tangible Fixed Assets	667	-	-	667
Investments at valuation:-				
<i>Fixed asset investments</i>	1,674,963	-	-	1,674,963
Current Assets	13,058	26,886	18,679	58,623
Current Liabilities	(57,654)	-	-	(57,654)
	1,631,034	26,886	18,679	1,676,599

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2023 £	Movement in funds in 2024 See Note 18 £	Transfers between funds in 2024 See Note 19 £	Funds carried forward to 2025 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,631,034	115,436	8,497	1,754,967
Designated Revenue Funds	26,886	-	(8,408)	18,478
Total unrestricted and designated funds	1,657,920	115,436	89	1,773,445
Restricted funds:-				
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Arthritis Grand Challenge	67	-	(67)	-
Restricted - Metabolic Bone Disease	3,346	(397)	(22)	2,927
Total restricted funds	18,679	(397)	(89)	18,193
Total charity funds	1,676,599	115,039	-	1,791,638

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

18 Analysis of movements in funds over the year as shown in Note 17

	Income 2024 £	Expenditure 2024 £	Other Gains & Losses 2024 £	Movement in funds 2024 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	106,811	(238,208)	246,833	115,436
Restricted funds:-				
Restricted - Metabolic Bone Disease	75	(472)	-	(397)
	106,886	(238,680)	246,833	115,039

19 Details of transfers between

The transfers shown in note 17 above are:-	2024 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	8,497
To/(from) Designated Revenue Funds	(8,408)
To/(from) Restricted Revenue Funds	(89)
Net transfers	-

20 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds Funds specific for this purpose.

Restricted funds:-

Restricted Revenue Funds Funds specific for this purpose.

21 Ultimate controlling party

The charity is under the control of its legal members.
Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.



22 Donations, Grants and Legacies

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total Funds 2023 £
Donations and gifts from individuals				
Donations	38,462	-	38,462	52,301
Total donations and gifts from individuals	38,462	-	38,462	52,301
Legacies receivable				
Legacies receivable	2	-	2	39
Total legacies receivable	2	-	2	39

Total Donations, Grants and Legacies

Total Donations, Grants and Legacies	A1	38,464	-	38,464	52,430
---	-----------	---------------	----------	---------------	---------------

Notified of a share of the estate of Hedley John Stephens yet to be realised.

23 Income from charitable activities - Trading Activities

<i>Current year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2023 £	Prior Year Total Funds £
2024				
Primary purpose and ancillary trading				
Education income	1,923	75	1,998	43,287
Other and recharged income	105	-	105	1,139
Service charges - BGPRT	17,558	-	17,558	17,561
Service charges - BRIT PACT	4,964	-	4,964	4,658
Total Primary purpose and ancillary trading	24,550	75	24,625	66,645

Not all the trading activities in the prior year were unrestricted

<i>Prior Year</i>	Prior year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Primary purpose and ancillary trading			
Education income	43,287	-	43,287
Other and recharged income	989	150	1,139
Service charges - BGPRT	17,561	-	17,561
Service charges - BRIT PACT	4,658	-	4,658
Total Primary purpose and ancillary trading	66,495	150	66,645



24 Total Income from charitable activities

<i>Current year</i>		Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total Funds 2023 £
Total income from charitable trading		24,550	75	24,625	66,645
Total from charitable activities	A2	24,550	75	24,625	66,645

Not all the income in the prior year was unrestricted.
Income from charitable activities - Prior Year analysis

<i>Prior Year</i>	Prior year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Total income from charitable trading	66,495	150	66,645
	66,495	150	66,645

25 Investment income

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Dividend Income	43,797	-	43,797	44,462
Total investment income A4	43,797	-	43,797	44,462

26 Expenditure on charitable activities - Direct spending

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Labour costs - charitable activities	133,060	-	133,060	119,611
Education costs	7,269	472	7,741	42,273
PPE Project costs	2,344	-	2,344	8,545
Total direct spending	B2a	472	143,145	170,429

Not all the expenditure in the prior year was unrestricted.

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

27 Expenditure on charitable activities- Grant funding of activities

<i>Current Year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Grants made to individuals	63,776	-	63,776	49,739
Total grantmaking costs B2c	63,776	-	63,776	49,739

28 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Premises Expenses				
Rent	3,300	-	3,300	6,000
Administrative overheads				
Telephone, fax and internet	1,034	-	1,034	760
Stationery and printing	1,151	-	1,151	423
Marketing and promotion	14,926	-	14,926	5,307
Registration and licensing	1,622	-	1,622	1,068
IT support costs	2,380	-	2,380	1,867
Sundry expenses	-	-	-	720
Recharged expenses	72	-	72	1,189
Insurance	547	-	547	440
Trustees costs	177	-	177	-
Hospitality	472	-	472	-
Travel	20	-	20	67
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	4,033	-	4,033	3,660
Other legal and professional	1,017	-	1,017	1,526
Financial costs				
Bank charges	116	-	116	116
Depreciation	430	-	430	276
Total support costs	31,297	-	31,297	23,419

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Prior Year Total Funds 2023 £
Recharged expenses	595	594	1,189
Support costs before reallocation	22,825	594	23,419
Total support costs - Prior Year	22,825	594	23,419

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

29 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Independent Examiner's fees	462	-	462	450
Total Governance costs	462	-	462	450

All the expenditure in the prior year was unrestricted.

30 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Total direct spending	B2a	142,673	472	143,145	170,429
Total grantmaking costs	B2c	63,776	-	63,776	49,739
Total support costs	B2d	31,297	-	31,297	23,419
Total Governance costs	B2e	462	-	462	450
Total charitable expenditure B2		238,208	472	238,680	244,037

<i>Prior Year</i>		Prior year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Total direct spending	B2a	170,429	-	170,429
Total grantmaking costs	B2c	49,739	-	49,739
Total support costs	B2d	22,825	594	23,419
Total Governance costs	B2e	450	-	450
Total charitable expenditure B2		243,443	594	244,037



GRANTS AWARDED
FOR RESEARCH
£63,551



415
HEALTH
PROFESSIONALS
ATTENDING
TRAINING
SESSIONS



15
OPPORTUNITIES
TO PARTICIPATE IN
RESEARCH
OFFERED TO
PATIENTS



90%
OF THOSE
ATTENDING THE
RESEARCH
SHOWCASE SAID
THEY WERE MORE
LIKELY TO GET
INVOLVED IN
RESEARCH



20,000
LISTENS TO
PODCASTS

**Overall, the charity's
beneficiaries: scientific
academia and patients,
carers and their
families benefitted from
better understanding of
rheumatic diseases and
their treatment, thereby
contributing to the
alleviation of suffering.**



Bath Institute for Rheumatic Diseases

Supporting arthritis research, education
and patient engagement

**ANNUAL REPORT
AND
ACCOUNTS
*31 March 2024***

Company Registration Number 02908933
Charity Registration Number 1040650

Accounts



Company Registration Number 02908933
Charity Registration Number 1040650

Trustees' Annual Report for the year ended 31 March 2023

Contents	Page
Charity information	1
Trustees' Annual Report	2
Statement of directors' responsibilities	11
Independent Examiner Report	13
Funds Statements:-	
Statement of Financial Activities	15
Statement of Financial Activities - Prior Year statement	16
Statement of total recognised gains and losses	17
Movements in funds	18
Revenue Funds	18
Income and Expenditure account	19
Balance sheet	20
Notes to the accounts	22



Trustees' Annual Report for the year ended 31 March 2023

Charity information

The Trustees present their Report and Accounts for the year ended 31 March 2023, which also comprises the Directors' Report required by the Companies Act 2006.

The charity name.

The legal name of the charity is:-
Bath Institute for Rheumatic Diseases.
The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650. The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Department D1
Wolfson Building, Royal United Hospital Bath,
BA1 3NG
Telephone 01225 336363

BIRD@birdbath.org.uk
www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office for the period covered by the report:

Mr C Johns (*Chair*)
Dr A Mackenzie
Prof N McHugh
Prof B Morley (*Acting Chair from September 2022*)
Prof R Sengupta
Mr J Sherwin
Dr W Tillett
Mr S O'Reilly
Mrs L Snelus



Trustees' Annual Report for the year ended 31 March 2023

Objects and activities of the charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

We finish the financial year with £1,676,599 in funds, down from £1,819,505 at the same point last year. Income was up 32% (due in particular to a trebling of income from charitable activities, ie pharmaceutical sponsorship and grants for our Patient Education programme and the biennial Skin Conference income).

Expenditure was up 35% reflecting an increase in contractors' costs and expanded marketing activity to generate awareness and fundraising. This was a difficult year for investment growth following the outbreak of war and fuel crisis and our investments lost £62,316 overall (against a growth of £132,320 last year). BIRD awarded £49,739 in grants and bursaries to clinician researchers and early career researchers.

Strategy

A new strategy was produced to 2030 with the central purpose of balancing reliance on investment performance over the long term with more grant and donor fundraising, which in turn requires a raised profile and clearer articulation of impact. A four minute animation summarising BIRD's work was produced for this purpose and can be found here <https://www.birdbath.org.uk/news/new-film-introducing-bird-and-our-work>.

Highlights

- *BIRD won 'highly commended', second to the overall winners of the Bath Life Awards In March 2023*
- *Reaching the 10,000 milestone in listens to BIRD podcasts for patients*
- *Running the third Skin at Bath symposium*
- *BIRD attending the British Society of Rheumatologists conference with a stand presenting Patient Engagement work*
- *BIRD helped to organise the first Research Showcase event in Bath, showcasing the research of early career researchers from the RNHRD and the University for members of the public on BIRD's databases*
- *Launching the Nick Hall Bursary scheme and formalizing bursaries for attendance at BSR*

Grants awarded for research

BIRD funds research projects in rheumatic diseases which:

- Help to promote and advance medical knowledge
- Improve treatments for patients
- Encourage collaboration between clinicians and research scientists
- Supports the next generation of researchers into bone and joint diseases

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

Recent evaluation of BIRD's research grant programme since 2016 confirmed that it has



Trustees' Annual Report for the year ended 31 March 2023

achieved its intended functions of promoting and advancing medical science, pump-priming research, helping researchers in the early stages of their careers, helping clinicians to be research active, encouraging collaborations between clinicians and research scientists, and ensuring patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded over 22 projects, with at least 20 published academic papers and 537 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

In total, £49,738.80 was awarded

£19,998.00 to Özgür Şimşek, for a project in Data Analytics looking at patient scheduling which has the potential to change the way rheumatology patients are managed via computer learned patterns meaning that those patients who need to be seen by a specialist can be seen promptly, thus improving clinical outcomes and the patient experience.

£20,000 to Dr Ben Mulhearn for investigating how common VEXAS syndrome is in an adult rheumatology population. This is a multicentre study over three NHS Trusts in South West England. The committee agreed this is a novel project in an area under-researched, therefore potentially giving a higher impact to the patient population.

£3,120 to Louis Godtfredsen for a Summer Studentship for an undergraduate student in the area of arthritis research. This year's studentship provided hands-on experience of data-based research to give Louis a taster of what a career in research would offer. He worked with supervisors on the project 'Automating the BASMI Measurement Using Pose Tracking on a Smartphone'. He now intends to follow a career in medical research,

Louis said: "The past two months have played a pivotal role in my decision on whether I wish to pursue research as a career.

I can gladly say that I believe that is where I am headed and in large part due to the BIRD Studentship, so much so that not only do I wish to pursue research but, interdisciplinary research in medicine and computer science.

I can proudly say I would score the studentship a solid ten for the impact it has had on me and my future career decisions."

Trustees' Annual Report for the year ended 31 March 2023



BIRD co-hosted the third Skin@Bath Network Symposium with 170 participants from 13 countries, 103 of whom attended the event in person. Over 55 talks and 26 posters were presented within two days by prestigious national and international clinicians, healthcare professionals and scientists as well as early career researchers, medical trainees and postgraduate students.

BIRD thanked Professor Ian White, Vice Chancellor and President of the University of Bath for his speech of welcome, the China-UK Skin Consortium partnership and the Symposium sponsors Pfizer, Sanofi, Abbvie and Janssen/Johnson & Johnson as well as the Faculty of Science, the Department of Life Sciences and the Centre for Therapeutic Innovation at the University of Bath.

To honour the memory of BIRD's former Chairman, Nick Hall, and to support the symposium which he co-founded, £2,000 was awarded for Nick Hall bursaries to provide travel bursaries to five early career researchers, medical trainees and postgraduate students.

Dr Nick Hall, is fondly remembered as a distinguished academic reader and a highly supportive Director of studies at the former Department of Pharmacy and Pharmacology of the University of Bath. He was also a dedicated mentor for early career researchers and junior

academic lecturers for whom he provided many opportunities for research within the field of rheumatic disease.

The Nick Hall Memorial Bursary will continue his legacy by financially supporting the participation of young researchers and medical trainees either at postgraduate or early career stages of their career to attend the Skin@Bath Network Symposium. Applicants are restricted to PhD students, postdoctoral researchers, and medical trainees and applications from less privileged countries are prioritised in the selection stage.

For the first time BIRD took a stand at the annual British Society for Rheumatology Conference in Glasgow to showcase the Patient Engagement programme. This was to promote and network for further patient engagement opportunities.



Two conference attendees had been awarded bursaries in a successful pilot and as a result a further £4,620 was awarded for bursaries to nine people to attend BSR and EULAR in 2023. This is to encourage health professionals based in the Royal National Hospital for Rheumatic Diseases (RNHRD) to attend these key national and international conferences as part of BIRD's mission to encourage clinical staff to be research-active and to maintain the RNHRD's reputation for research excellence.



Trustees' Annual Report for the year ended 31 March 2023



BIRD co-hosted the RNHRDs first Research Showcase Event at the Bath Royal Literary and Scientific Institute in March 2023 together with Royal United Hospital Bath, GW4 and the University of Bath.

15 Consultants and early career researchers from the RNHRD gave talks on their research and showed 12 research posters for 48 members of the general public. The feedback was so positive that BIRD plan to repeat the showcase next year.

"I found the talks all very informative, very interesting and very beautifully presented by the professionals. I am very grateful to have attended and would love to come to other similar events. I hope that there will be more".



BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education & Research Trust. The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration, support, including the accreditation and sponsorship where necessary, for educational events reaching **580** healthcare professionals (includes **170** biennial skin conference attendees), **223** more attendees than last year 2021/22. Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

Three Bath Inflammation and Immunology Research Group meetings were held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time. This meeting was renamed Rheumatology Research @ Bath.

Joint Injection Training for GPs, Nurse Practitioners and Primary Care Healthcare Professionals took place in April 2022.

Two Bath & Bristol bone meetings were held in April and November 2022 for consultants and clinical staff.

Trustees' Annual Report for the year ended 31 March 2023

The South West Axial Spondyloarthritis Group was held in November 2022.

The South West CTD & Vasculitis Meeting was held in March 2023.

An awayday for Rheumatology staff from the RNHRD was organized by BIRD to address waiting times and patient initiated follow up.

The Primary Care Rheumatology Update afternoon was postponed due to doctors strike to April 2023 so will fall into the next financial years report.

Qualitative feedback collected from some of the sessions showed that participants rated talks either 'excellent' or 'good' with most comments finding the training "helpful" and a useful update,

"Great meeting - all presentations excellent and very useful discussion. The meeting was very well organised and chaired."

"The hybrid option is really valuable and great to see so many attendees online. Great selection of speakers. Fantastic external speakers. Good to see some younger investigators given chance to present and raise their profiles within the region."

"Thank you, one of the most useful couple of hours I've ever had in training!"

"A truly fantastic & well organised session - thank you so much"

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.

The Patient and Public Engagement Programme

The Programme vision is to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment. With the twin aims of:

1. Patients have a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals
2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke since 2016, the programme has continuously evolved and developed around patient audience needs. It provides opportunities for them to connect, learn and share through a flexible and innovative mix of media.

Podcasts - covering a range of rheumatology conditions, these now reach thousands of patients and their families, across the country (and beyond) heavily promoted on social media.

Over the year Mel Brooke produced another 15

new podcasts bringing the library to 50 and achieving an amazing 10,000 listens. New topics covered were Lupus, Sjogrens, Psoriatic Arthritis, Fibromyalgia, Raynaud's Syndrome and new NICE Guidelines.



Trustees' Annual Report for the year ended 31 March 2023

Webinars - were developed, providing live events online that give patients access to consultants and experts' presentations and the opportunity to ask questions. 215 patients attended three webinars on Axial Spondyloarthritis, Psoriatic Arthritis and Rheumatoid Arthritis.

Research - patients tell us they are keen to 'give back' and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. Patients were invited to participate in 15 research requests and surveys.

Patient Research Panel – 26 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year

Patient Advisory Groups – the Patient Engagement Director helped to shape and advise the Lupus Patient Advisory Group twice during the year and the University of Bath Patient and Public Involvement group once.

Patient centered culture - we work hard to understand and accommodate patient needs and provide what is meaningful to them, through formative survey, feed back and involvement in the governance of BIRD. Three new cases studies were produced to tell patients' stories, especially around their motivations and experiences of getting involved in research.



Patients said:

- *I listened to the Lupus episodes and thought they were brilliant.*
- *Today I listened to Sjögren's episodes and shared them with my support group which includes people with this condition.*
- *I'm listening to lots of BIRD podcasts at the moment. On my 5th. They are brilliant.*
- *I'm listening to Myositis podcasts... what amazes me is the depth and range of information in each podcast.*
- *Very accessible. Learning new language to explain things.*
- *I just want to thank you very much for your podcasts on the subject of Psoriatic Arthritis. As someone newly diagnosed with this disease I found them so informative and helpful.*

Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook advertising for the podcasts, with over 200,000 people getting the opportunity to see a BIRD advertisement for the podcasts. BIRD's subscriber database grew by 60% across Twitter, Facebook, Mailchimp and LinkedIn.



Trustees' Annual Report for the year ended 31 March 2023

Particular success was achieved in celebrating the 10,000 listens to podcasts milestone, achieving good coverage in local press and BBC radio. This led to BIRD being nominated in the Bath Life Awards in the Charity category, received a unique 'Highly Commended' award for the Patient Information Podcast library for rheumatology conditions.

Effort spent in seeking to attract grants from pharmaceutical companies for the Patient Engagement programme was rewarded with £30,000 in grants and sponsorship from Lily, UCB and Biogen. This was largely due to the excellent performance of the podcasts and advertising them widely on social media, which attracted thousands of listeners.

The Skin conference also attracted significant pharma sponsorship for the first time, based on more clinical attendance and promotional work by the organizing team. Thank you to Pfizer, Sanofi, Abbvie and Janssen.

Further grants were awarded to the Patient and Public Engagement programme by Medlock Charitable Trust, Stone King, Arnold Clark Community Fund, Roper Family Trust, Ray Harris Community Trust and Champriss Community Trust. Many individuals also gave donations for which BIRD is grateful.

The main achievements and performance of the charity in terms of public benefit

The total amount of grants awarded for research into rheumatic diseases was **£49,738.80**

580 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

10,000 listens to podcasts for patients, and 60% growth in patient subscribers across all platforms. The total network reached via mailings and social media ad postings exceeded 200,000 patients and members of the public.

74% of listeners to podcasts said their knowledge of their condition had improved as a result.

15 opportunities to participate in research, were offered to patients, 26 members of the patient research panel responded to 5 new research opportunities.

90% of attendees to the Research Showcase said they were more likely to get involved in research.

A Lupus Patient Advisory Panel and the University of Bath PPI were advised by BIRD's PPE Director.

Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and Hospital.

New charitable trusts supported BIRD's work with grants and pharmaceutical companies increasing their levels of support.

BIRD recruited two new Trustees and five new committee members during the year.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Trustees' Annual Report for the year ended 31 March 2023

Structure, governance and management of the charity

The governing body is the Council of Management made up of 9 trustees. The chair is now Professor Bernie Morley emeritus, Council of Management meets quarterly.

Three committees report to the Council of Management.

These are the quarterly **Finance Committee**, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns and Linda Snelus; the **biannual Research Committee**, chaired by Professor Bernie Morley emeritus, members are Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr Sarah Skeoch, Dr Paula Smith, Dr Theresa Smith, Frank Sweeting and Dr Sarah Tansley; and the quarterly **Education & Engagement Committee**, chaired by Shane O'Reilly, members are Dr Andrew Allard, Patricia Mattinson and Jessie Naish. All committees are supported by relevant contract staff in attendance.

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham B1 2HB

CCLA Investment Management Ltd, COIF Charity Funds, 1 Angel Lane, London EC4R 3AB

Solicitors

Stone King, 13 Queen Square, Bath BA1 2HJ

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath BA1 3RU

Financial review

The financial position of the charity at 31 March 2023 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2023 £	2022 £
Net income	(142,906)	117,107
Unrestricted Revenue Funds available for the general purposes of the charity	1,631,034	1,778,291
Designated Revenue Funds	26,886	21,513
Total Unrestricted Funds	1,657,920	1,799,804
Restricted Revenue Funds	18,679	19,701
Total Funds	1,676,599	1,819,505

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.



Trustees' Annual Report for the year ended 31 March 2023

BIRD's reserves policy is to

- hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised.

Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received and will encourage clinicians to undertake research and early stage career researchers with their development through enhanced numbers of bursaries for conference attendance.

BIRD will help thousands of patients to understand their disease and treatment better and, with renewed focus, hundreds of patients to engage with research.

BIRD will continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers to work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention financially is to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. A modest amount more will therefore be spent on marketing and awareness raising activity, especially in the area of legacy impact.



Trustees' Annual Report for the year ended 31 March 2023

Details of The Independent Examiner

Tom Case
Member of The Institute of Chartered
Accountants in England and Wales
20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



Trustees' Annual Report for the year ended 31 March 2023

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions
The financial statements are set out on pages 15 to 34.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 5 December 2023.



Professor Bernie Morley emeritus
Chair



Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2023

I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 34 for the year ended 31 March 2023 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 21.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider



Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2023

in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide.

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion


Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
- and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
- accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;
- the financial statements do not accord with those records; or

- the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;
- have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-



Tom Case - Independent Examiner

The Institute of Chartered Accountants in England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire SN14 0SY

This report was signed on 5 December 2023.



Statement of Financial Activities for the year ended 31 March 2023

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023 £	2023 £	2023 £	2022 £
Income & Endowments from:					
Donations & Legacies	A1	52,340	-	52,340	55,858
Charitable activities	A2	66,570	75	66,645	20,729
Investments	A4	44,462	-	44,462	47,199
Total income	A	163,372	75	163,447	123,786
Expenditure on:					
Charitable activities	B2	242,940	1,097	244,037	180,894
Total expenditure	B	242,940	1,097	244,037	180,894
Net gains/(losses) on investment	B4	(62,316)	-	(62,316)	132,320
Net income for the year		(141,884)	(1,022)	(142,906)	75,212
Net income after transfers	A-B-C	(141,884)	(1,022)	(142,906)	75,212
Other recognised gains/(losses)					
Extraordinary items	D3	-	-	-	41,895
Net movement in funds		(141,884)	(1,022)	(142,906)	117,107
Reconciliation of funds:-	E				
Total funds brought forward		1,799,804	19,701	1,819,505	1,702,398
Total funds carried forward		1,657,920	18,679	1,676,599	1,819,505

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.

All activities derive from continuing operations

The notes attached on pages 22 - 37 form an integral part of these accounts



Statement of Financial Activities for the year ended 31 March 2023

Analysis of prior year total funds as required by paragraph 4.2 of the SORP

	SORP Ref	Prior year Unrestricted Funds £	Prior year Restricted Funds £	Prior Year Total Funds £
Income & Endowments from:				
Donations & Legacies	A1	55,858	-	55,858
Charitable activities	A2	20,579	150	20,729
Other trading activities	A3	-	-	-
Investments	A4	47,199	-	47,199
Other	A5	-	-	-
Total income	A	123,636	150	123,786
Expenditure on:				
Raising funds	B1	-	-	-
Charitable activities	B2	180,300	594	180,894
Other	B3	-	-	-
Tax on surplus on ordinary activities	B3	-	-	-
Other taxation	B3	-	-	-
Total expenditure	B	180,300	594	180,894
Net gains/(losses) on investments	B4	132,320	-	132,320
Net income for the year		75,656	(444)	75,212
Transfers between funds	C	-	-	-
Net income after transfers		75,656	(444)	75,212
Extraordinary items	D3	41,895		41,895
Net movement in funds		117,551	(444)	117,107
Reconciliation of funds:-	E			
Total funds brought forward		1,682,253	20,145	1,702,398
Total funds carried forward		1,799,804	19,701	1,819,505

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 22 - 37 form an integral part of these accounts



Statement of Financial Activities for the year ended 31 March 2023

Statement of Total Recognised Gains and Losses for the year ended 31 March 2023

	2023 £	2022 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(80,590)	(57,108)
Income from operations before tax in the Statement of Financial Activities	(80,590)	(57,108)
Realised (losses)/gains on investments	(710)	(2,104)
Extraordinary items	-	41,895
Surplus as shown in the Income and Expenditure account	(81,300)	(17,317)
Unrealised (losses)/gains on investments	(61,606)	134,424
Net Movement in funds before taxation	(142,906)	117,107
Funds generated in the year as shown on Statement of Financial Activities	(142,906)	117,107
Resources applied in the year ended 31 March 2023 towards fixed assets for Charity use		

	2023 £	2022 £
Funds generated in the year as detailed in the SOFA	(142,906)	117,107
Net resources available to fund charitable activities	(142,906)	117,107

Movements in revenue and capital funds for the year ended 31 March 2023

Revenue accumulated funds

	Unrestricted Funds 2023 £	Restricted Funds 2023 £	Total Funds 2023 £	Last year Total Funds 2022 £
Accumulated funds brought forward	1,799,804	19,701	1,819,505	1,702,398
Recognised gains and losses before transfers	(141,884)	(1,022)	(142,906)	75,212
	1,657,920	18,679	1,676,599	1,777,610
Exceptional items	-	-	-	41,895
Closing revenue funds	1,657,920	18,679	1,676,599	1,819,505

The notes attached on pages 22 - 37 form an integral part of these accounts



Statement of Financial Activities for the year ended 31 March 2023

Designated revenue funds included within the unrestricted funds above

	Total Funds 2023 £	Last year Total Funds 2022 £
At 1 April	21,513	14,666
Transfer (to)/from revenue accumulated funds	5,373	6,847
At 31 March	26,886	21,513

The purposes for which these funds have been designated are described in Note 21 to the accounts.

Summary of funds	Unrestricted and Designated funds £ 2023	Restricted Funds £ 2023	Total Funds £ 2023	Last Year Total Funds £ 2022
Revenue accumulated funds	1,631,034	18,679	1,649,713	1,797,992
Revenue designated funds	26,886	-	26,886	21,513
Total funds	1,657,920	18,679	1,676,599	1,819,505

The notes attached on pages 22 - 37 form an integral part of these accounts

Statement of Financial Activities for the year ended 31 March 2023

Income and Expenditure Account for the year ended 31 March 2023 as required by the Companies Act 2006

	2023 £	2022 £
<i>Income</i>		
Income from operations	118,985	76,587
Realised gains/(losses) on investments	-	(2,104)
Investment income		
Income from investments, other than interest receivable	44,462	47,199
Gross income in the year before exceptional items	163,447	121,682
Gross income in the year including exceptional items	163,447	121,682
<i>Expenditure</i>		
Charitable expenditure, excluding depreciation and amortisation	243,311	180,180
Depreciation and amortisation	276	276
Governance costs	450	438
Realised losses on the disposal of investments	710	-
Total expenditure in the year	244,747	180,894
Extraordinary items	-	(41,895)
Net income before tax in the financial year	(81,300)	(17,317)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(81,300)	(17,317)
Retained surplus for the financial year	(81,300)	(17,317)

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 22 - 37 form an integral part of these accounts



Balance Sheet as at 31 March 2023

Balance Sheet as at 31 March 2023

	Note	SORP Ref	2023 £	2022 £
Fixed assets		A		
Tangible assets	10	A2	667	943
Investments held as fixed assets	11	A4	1,674,963	1,736,569
Total fixed assets			1,675,630	1,737,512
Current assets		B		
Debtors	13	B2	9,628	18,284
Cash at bank and in hand		B4	48,995	151,545
Total current assets			58,623	169,829
Creditors: amounts falling due within one year	14	C1	(57,654)	(87,836)
Net current assets			969	81,993
The total net assets of the charity			1,676,599	1,819,505

The total net assets of the charity are funded by the funds of the charity, as follows:-

Restricted funds				
Restricted Revenue Funds	18	D2	18,679	19,701
Unrestricted Funds				
Unrestricted Revenue Funds	18	D3	1,631,034	1,778,291
Designated Funds				
Designated Revenue Funds	18	D3	26,886	21,513
Total charity funds			1,676,599	1,819,505

The notes attached on pages 22 - 37 form an integral part of these accounts



Balance Sheet as at 31 March 2023

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.



James Sherwin

Trustee and Chair of the Finance Committee
Approved by the board of trustees on 5
December 2023

Notes to the Accounts for the year ended 31 March 2023

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material

uncertainties about the charity's ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the

Notes to the Accounts for the year ended 31 March 2023

statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the

criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.



Notes to the Accounts for the year ended 31 March 2023

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery 20 % reducing balance

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity. Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.

There are no endowment funds.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied

Notes to the Accounts for the year ended 31 March 2023

exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Significance of financial instruments to the charity's position

There are no significant implications of financial instruments to the charity's financial position or performance.

5 Net surplus before tax in the financial year

The net surplus before tax in the financial year is stated after charging:-

Depreciation of owned fixed assets:

2023	2022
£ 276	£ 276



Notes to the Accounts for the year ended 31 March 2023

6 Investment gains

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
<i>Realised gains/(losses)</i>				
Listed investments	(710)	-	(710)	(2,104)
Total realised gains/(losses)	(710)	-	(710)	(2,104)
<i>Unrealised gains /(losses) and writing down of carrying values</i>				
Listed investments - Unrealised	(61,606)	-	(61,606)	134,424
Total unrealised gains/(losses)	(61,606)	-	(61,606)	134,424
Total unrealised gains/(losses)	(62,316)	-	(62,316)	132,320

All the gains and losses in the prior year was unrestricted.

Prior year

	Prior Year Unrestricted Funds 2022	Prior Year Restricted Funds 2022	Prior Year Total Funds 2022
	£	£	£
Realised gains/(losses)			
Listed investments	(2,104)	-	(2,104)
Total realised gains/(losses)	(2,104)	-	(2,104)
<i>Unrealised gains /(losses) and writing down of carrying values</i>			
Listed investments - Unrealised	134,424	-	134,424
Total unrealised gains/(losses)	134,424	-	134,424
Total realised and unrealised gains	132,320	-	132,320



Notes to the Accounts for the year ended 31 March 2023

7 Extraordinary items - analysed by fund

	2023 £	2022 £
<i>Total extraordinary items</i>	-	(41,895)
	-	(41,895)

This item comprises £23,085 of a cancelled grant from previous years and £18,810 of an underspend from the funded clinical lectureship finishing earlier than awarded, due to promotion.

8 Staff costs and emoluments

Labour costs	2023 £	2022 £
Gross salaries, labour and related costs	119,611	99,490
	119,611	99,490

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

9 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.



Notes to the Accounts for the year ended 31 March 2023

10 Tangible fixed assets

Current Year	Plant & Machinery	Total
	£	£
Cost		
At 1 April 2022	11,940	11,940
At 31 March 2023	11,940	11,940
Depreciation		
At 1 April 2022	10,997	10,997
Charge for the year	276	276
At 31 March 2023	11,273	11,273
Net book value		
At 31 March 2023	667	667
At 31 March 2022	943	943

11 Investments held as fixed assets

	Investment in subsidiaries	Listed investments	Total
	£	£	£
Carrying values of investments			
At 1 April 2022	2	1,736,567	1,736,569
Revaluation at 31 March 2023	-	(61,606)	(61,606)
At 31 March 2023	2	1,674,961	1,674,963
Analysis between fair value and historical cost			
Investments as above held at fair value	2	1,674,961	1,674,963

Notes to the Accounts for the year ended 31 March 2023

12 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the eight years ending 31st March 2023.

A summary of the unaudited financial statements of the subsidiary is :-

	2023 £	2022 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)

Profit and Loss

Net profit for the year before tax	-	-
Net profit for the year after tax and Gift Aid	-	-

Funds retained within charitable subsidiaries

	2023 £	2022 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	-	-

13 Debtors

	2023 £	2022 £
Trade debtors	8,767	6,812
Prepayments and accrued income	861	11,472
	9,628	18,284

14 Creditors: amounts falling due within one year

	2023 £	2022 £
Trade creditors	14,325	29,191
Accruals	6,600	600
Other creditors	36,729	58,045
	57,654	87,836



Notes to the Accounts for the year ended 31 March 2023

15 Income and Expenditure account summary

	2023 £	2022 £
At 1 April 2022	1,685,081	1,702,398
Surplus after tax for the year	(81,300)	(17,317)
At 31 March 2023	1,603,781	1,685,081

16 No related party transactions

There were no transactions with related parties in the year.

17 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2023	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	667	-	-	667
Investments at valuation:-				
<i>Fixed asset investments</i>	1,674,963	-	-	1,674,963
Current Assets	13,058	26,886	18,679	58,623
Current Liabilities	(57,654)	-	-	(57,654)
	1,631,034	26,886	18,679	1,676,599

At 1 April 2022	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	-	943	-	943
Investments at valuation:-				
Fixed asset investments	1,736,569	-	-	1,736,569
Current Assets	128,615	21,513	19,701	169,829
Current Liabilities	(87,836)	-	-	(87,836)
	1,778,291	21,513	19,701	1,819,505



Notes to the Accounts for the year ended 31 March 2023

18 Change in total funds over the year as shown in Note 17, analysed by individual funds

	Funds brought forward from 2022	Movement in funds in 2023	Transfers between funds in 2023	Funds carried forward to 2024
	£	See Note 19 £	See Note 20 £	£
<i>Unrestricted and designated funds:-</i>				
Unrestricted Revenue Funds	1,778,291	(141,884)	(5,373)	1,631,034
Designated Revenue Funds	21,513	-	5,373	26,886
Total unrestricted and designated funds	1,799,804	(141,884)	-	1,657,920
<i>Restricted funds:-</i>				
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - CRPS Network UK	1,097	(1,097)	-	-
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Arthritis Grand Challenge	67	-	-	67
Restricted - Metabolic Bone Disease	3,271	75	-	3,346
Total restricted funds	19,701	(1,022)	-	18,679
Total charity funds	1,819,505	(142,906)	-	1,676,599

19 Analysis of movements in funds over the year as shown in Note 18

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2023	2023	2023	2023
	£	£	£	£
<i>Unrestricted and designated funds:-</i>				
Unrestricted Revenue Funds	163,372	(242,940)	(62,316)	(141,884)
<i>Restricted funds:-</i>				
Restricted - CRPS Network UK		(1,097)	-	(1,097)
Restricted - Metabolic Bone Disease	75	-	-	75
	163,447	(244,037)	(62,316)	(142,906)

Notes to the Accounts for the year ended 31 March 2023

20 Details of transfers between

<i>The transfers shown in note 18 above are:-</i>	2023
	£
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	-
To/(from) Designated Revenue Funds	(5,373)
To/(from) Restricted Revenue Funds	5,373
Net transfers	-

21 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use

Designated Revenue Funds Funds specific for this purpose.

Restricted funds:-

Restricted Revenue Funds Funds specific for this purpose.

22 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.



Detailed Analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

23 Donations, Grants and Legacies

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Donations and gifts from individuals				
Donations	52,301	-	52,301	55,858
Total donations and gifts from individuals	52,301	-	52,301	55,858

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Legacies receivable				
Legacies receivable	39	-	39	-
Total legacies receivable	39	-	39	
Total Donations, Grants and Legacies A1	52,340	-	52,340	55,858

24 Income from charitable activities - Trading Activities

<i>Current year</i>	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total funds 2023 £	Prior Year Total Funds 2022 £
Primary purpose and ancillary trading				
Education income	43,212	75	43,287	625
Other and recharged income	1,139	-	1,139	3,615
Service charges - BGPRT	17,561	-	17,561	11,723
Service charges - BRIT PACT 11,723	4,658	-	4,658	4,766
Total Primary purpose and ancillary trading	66,570	75	66,645	20,729

Not all the trading activities in the prior year were unrestricted

<i>Prior Year</i>	Prior year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
Primary purpose and ancillary trading			
Other and recharged income	3,465	150	3,615
Total Primary purpose and ancillary trading	20,579	150	20,729



Detailed Analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

25 Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Prior Year Total Funds	Current year Total Funds
	2023 £	2023 £	2023 £	2022 £
Total income from charitable trading	66,570	75	66,645	20,729
Total from charitable activities A2	66,570	75	66,645	20,729

Not all the income in the prior year was unrestricted.

Income from charitable activities - Prior Year analysis

<i>Prior Year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior year Total Funds
	2022 £	2022 £	2022 £
Total income from charitable trading			
Income from funders	20,579	150	20,729
-	20,579	150	20,729

26 Investment income

	Current year Unrestricted Funds 2023	Current year Restricted Funds 2023	Current year Total Funds 2023	Prior Year Total Funds 2022
	£	£	£	£
Dividend Income	44,462	-	44,462	47,199
Total investment income A4	44,462	-	44,462	47,199



Detailed Analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

27 Expenditure on charitable activities - Direct spending

<i>Current Year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023 £	2023 £	2023 £	2022 £
Labour costs - charitable activities	119,611	-	119,611	99,490
Education costs	41,176	1,097	42,273	1,042
PPE Project costs	8,545	-	8,545	4,709
Total direct spending B2a	169,332	1,097	170,429	105,241

Not all the expenditure in the prior year was unrestricted.

28 Expenditure on charitable activities- Grant funding of activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Prior Year Total Funds	Total Funds
	2023 £	2023 £	2023 £	2022 £
Grants made to individuals	49,739	-	49,739	55,047
Total grantmaking costs B2c	49,739	-	49,739	55,047

29 Support costs for charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Prior Year Restricted Funds	Total Funds	Total Funds
	2023 £	2023 £	2023 £	2022 £
Premises Expenses				
Rent	6,000	-	6,000	5,550
Administrative overheads				
Telephone, fax and internet	760	-	760	720
Stationery and printing	423	-	423	409
Marketing and promotion	5,307	-	5,307	1,174
Registration and licensing	1,068	-	1,068	657
IT support costs	1,867	-	1,867	1,288
Sundry expenses	720	-	720	168
Recharged expenses	1,189	-	1,189	4,713
Insurance	440	-	440	439
Hospitality	-	-	-	57
Travel	67	-	67	-



Detailed Analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Professional fees paid to advisors other than the auditor or examiner

Accountancy fees other than examination or audit fees	3,660	-	3,660	3,060
Other legal and professional	1,526	-	1,526	1,497
Financial costs				
Bank charges	116	-	116	160
Depreciation	276	-	276	276
Total support costs - Current Year	23,419	-	23,419	20,168

<i>Prior Year</i>	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior year Total Funds
	2022 £	2022 £	2022 £
Recharged expenses	4,119	594	4,713
Total support costs - Prior Year	19,574	594	20,168

30 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds 2023	Current year Restricted Funds 2023	Current year Total Funds 2023	Prior Year Total Funds 2022
	£	£	£	£
Independent Examiner's fees	450	-	450	438
Total Governance costs	450	-	450	438

All the expenditure in the prior year was unrestricted.

Detailed Analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

31 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023 £	2023 £	2023 £	2022 £
Total direct spending	B2a	169,332	1,097	170,429	105,241
Total grantmaking costs	B2c	49,739	-	49,739	55,047
Total support costs	B2d	23,419	-	23,419	20,16
Total Governance costs	B2e	450	-	450	438
Total charitable expenditure	B2	242,940	1,097	244,037	180,894

<i>Prior Year</i>		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior year Total Funds	
		2022 £	2022 £	2022 £	
Total direct spending	B2a	105,241	-	105,241	
Total grantmaking costs	B2c	55,047	-	55,047	
Total support costs	B2d	19,574	594	20,168	
Total Governance costs	B2e	438	-	438	
Total charitable expenditure	B2	180,300	594	180,894	





Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

ANNUAL REPORT AND ACCOUNTS


31 March 2023

Company Registration Number 02908933
Charity Registration Number 1040650

Accounts



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement



Annual Report and Accounts

31 March 2022

Company registration number 02908933 | Charity registration number 1040650



Charity Information	1
Trustees' Annual Report	2
Statement Of Directors' Responsibilities	8
Independent Examiner's Report	11
 Funds Statements:	
Statement Of Financial Activities	13
Statement Of Financial Activities - Prior Year Statement	14
Statement Of Total Recognised Gains And Losses	15
Movements In Funds	16
Revenue Funds	16
Income And Expenditure Account	18
Balance Sheet	19
 Notes To The Accounts	22



The Trustees present their Report and Accounts for the year ended 31 March 2022, which also comprises the Directors' Report required by the Companies Act 2006.

Charity Name

The legal name of the charity is: Bath Institute for Rheumatic Diseases.

The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered with the Charity Commission in England & Wales (CCEW) with charity number 1040650.

The charity does not operate in any overseas jurisdictions.

Legal structure of the Charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:

Department D1
Wolfson Building
Royal United Hospital
Bath
BA1 3NG

Telephone: 01225 336363

Email Address: BIRD@birdbath.org.uk

Web Address: www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in Office on the Date the Report was Approved were:

Dr N Hall (resigned 29th April 2021)
Mr C Johns (Chair)
Ms S Lear (resigned 15th March 2022)
Dr A Mackenzie
Prof N McHugh
Prof B Morley (appointed 25th May 2021)
Dr J Pauling (resigned 15th March 2022)
Dr R Sengupta
Mr J Sherwin
Dr W Tillett



Objects and Activities of the Charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Response to the continuing Covid pandemic and economic climate

The Covid 19 pandemic continued to shape BIRD's operations during the period covered by this report. Most live events (patient engagement days and Education seminars for Healthcare Professionals, also the annual fundraising/awareness raising event) were cancelled and the office was closed. Consultant Trustees and other healthcare professionals on BIRD's committees, undertaking research and acting as podcast and webinar speakers were extremely busy addressing the backlog in patients.

The education programme for consultants, GPs, nurses and physiotherapists was also partly delivered online. And staff continued to work mainly from home.

We finish the financial year £117,000 ahead of last year on total funds. Income was up by a third, due to fundraising efforts, and expenditure was reduced to 80% of previous year mainly because of an unintended reduction in grant giving (being dependent on the quality of grant applications we receive, not all make it through the approval process). There was also an exceptional credit item of £41,895 in the accounts, which represents a cancelled project grant and an underspend in a grant from a previous year. The growth in the value of our investments grew by £132,320.

Grants awarded for Research

BIRD funds research projects in rheumatic diseases which:

- Help to promote and advance medical knowledge
- Improve treatments for patients

- Encourage collaboration between clinicians and research scientists
- Supports the next generation of researchers into bone and joint diseases

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

Recent evaluation of BIRD's research grant programme since 2016 confirmed that it has achieved its intended functions of promoting and advancing medical science, pump-priming research, helping researchers in the early stages of their careers, helping clinicians to be research active, encouraging collaborations between clinicians and research scientists, and ensuring patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded over 20 projects, with at least 20 published academic papers and 537 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

In total, £55,047 was awarded:

- **£14,695** to Dr Anita McGrogan and Dr Rachel Charlton for research into medication use during pregnancy and pregnancy outcomes in women with chronic inflammatory disease.
- **£19,766** to Dr William Tillet for research into identifying support needs for rheumatology patients following COVID-19 shielding.
- **£17,950** to Dr Sarah Tansley for researching novel biomarkers in Juvenile Dermatomyositis.
- **£2082** to Dr Sarah Tansley as the final instalment



in her National Institute for Health Research Clinical Lectureship.

- **£554** in bursaries for two clinicians, Dr Ben Mulhearn, Academic clinical fellow in Rheumatology and Jade Skeates, Rheumatology Physiotherapy Team Lead, to attend the British Society for Rheumatology conference in Glasgow, as part of a new BIRD bursary scheme to help early career stage specialists take up research.

BIRD took forward the first phase of recommendations from the previous year's research grant evaluation report by:

- Introducing a light touch process for capturing evidence of mid- to long term impact of its funding, capturing publications, follow on funding and real-world impact at 3- and 5-years post project points
- Encouraging proposals from allied health professionals
- Adding a panel member with social sciences/ qualitative research expertise to the Research Committee
- Exploring ways of telling stories about funded research, for example, capturing testimonies of patients involved in research through case studies



BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education & Research Trust. The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration, support, including the accreditation and sponsorship where necessary, for educational events reaching 357 healthcare professionals, significantly up from 254 last year and 300 the year before. Some face-to-face sessions, alongside online delivery were reinstated in hybrid sessions.

Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

Five Rheumatology Research group meetings were held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time. This meeting was renamed Bath Inflammation and Immunology Research Group.

The South West CTD & Vasculitis Meeting was held on 21 September 2021.

The Regional South-West Osteoporosis Meeting was held on 16 November 2021.

The South West Axial Spondyloarthritis Group was held on 23 November 2021.

The Primary Care Rheumatology Update afternoon was held on 29 March 2022.

Qualitative feedback collected from some of the sessions showed that participants rated talks either 'excellent' or 'good' with most comments finding the training "helpful" and a useful update, eg "a good summary reminding me of salient topics" and "brilliant afternoon with varied and interesting presentations". Participants had plenty of learning points to share with colleagues.

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.



The Patient and Public Engagement Programme

Our vision was restated during the year 'to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment'. With twin aims of:

1. Patients have a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals
2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke since 2016, the programme has continuously evolved and developed around patient audience needs. It provides opportunities for them to connect, learn and share through a flexible and innovative mix of media.

Podcasts covering a range of rheumatology conditions, these now reach thousands of patients and their families, across the country (and beyond) heavily promoted on social media. Over the year Mel Brooke produced 15 new podcasts bringing the library to 35 and achieving an amazing 3,950 listens. New topics covered were Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis, self-management and wellbeing topics of fatigue, sleep and social prescribing.

Webinars were introduced for the first time, providing live events online that give patients access to consultants and experts' presentations and the opportunity to ask questions. 48 patients attended these first webinars.

Research - patients tell us they are keen to 'give back' and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. Over 2,600 patients were invited to

participate and 251 patients got involved in research during the year.

Patient Research Panel - 21 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year Patient centered culture We work hard to understand and accommodate patient needs and provide what is meaningful to them, through formative survey, feed back and involvement in the governance of BIRD. Two new cases studies were produced to tell patients' stories.

Impacts

8,826 podcast listens in the two-year period April 2020 to April 2022

76% of listeners to podcasts understood their condition better as result

85 % reported increased confidence to live with their condition

85% felt empowered to make decisions about their treatments

75% reported that hearing voices of clinicians and healthcare practitioners was reassuring

58% reported the podcasts a help to their mental health - they felt supported, less isolated and part of a community

Patients said:

'I learnt a great deal about my condition and about possible ways to help myself. I was able to recognise and adapt some of the wider potential impacts of life and health choices'

'The more we as patients understand about Psoriatic Arthritis, the more effectively we can manage our condition'

'All useful, especially identifying with fellow sufferers'

'Everything was really interesting, educational and inspirational'

'My main motivation to participate in research opportunities is to hopefully help future generations and the current understanding of rheumatic diseases.'



Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook advertising for the podcasts, with over 200,000 people getting the opportunity to see a BIRD advertisement for the podcasts.

Effort spent in seeking to attract grants from pharmaceutical companies for the Patient Engagement programme began to pay off, and resulted in £43,000 in grants and awards. This was largely due to the excellent performance of the podcasts and advertising them widely on social media, which attracted thousands of listeners.

In November 2021 BIRD was delighted to win the international Amgen UPLIFT Innovation Challenge worth \$25,000 for its development of digital support for patients. Other pharmaceutical funders were Eli Lilly and Company Ltd and UCB.

Further grants were awarded to the Patient and Public Engagement programme by the Chamniss Charitable Trust, HealthWatch B&NES, Renishaw, The Saturday Hospital Fund, and the Siddons Charitable Trust.

Dr Ben Mulhearn ran the Palma half marathon and raised £1207 and a team of MBA students from the University of Bath raised £820 for BIRD's research funds.

The main achievements and performance of the charity in terms of public benefit

The total amount of grants awarded for research into rheumatic diseases was **£55,047**.

357 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

3,950 listens to podcasts for patients and 511 registered for newsletters. The total network reached via mailings and social media ad postings was estimated at almost 200,000 patients and members of the public.

76% of listeners to podcasts understood their condition better as result.

251 patients participated in research, and over 2,600 were invited to participate.

Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and Hospital.

Fundraising was greatly more than doubled, largely thanks to pharmaceutical grants but also thanks to the efforts of individuals.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefited from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.



Structure, governance and management of the charity

The governing body is the Council of Management made up of 9 trustees. The chair is Chris Johns. Council of Management meets quarterly.

Three committees report in to the Council of Management. These are the quarterly Finance Committee, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns and Linda Snelus; the biannual Research Committee, chaired by Professor Bernie Morley emeritus, members are Professor Rod Flower, Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr John Pauling, Dr Sarah Skeoch, Dr Paula Smith and Frank Sweeting; and the quarterly Education & Engagement Committee, chaired by Stephanie Lear, members are Dr Andrew Allard, Katie Burfitt, Judy Coles and Dr Patrick Ismond. All committees are supported by relevant contract staff in attendance.

Financial review

The financial position of the charity at 31 March 2022 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2022	2021
	£	£
Net income	117,107	172,928
Unrestricted Revenue Funds available for the general purposes of the charity	1,778,291	1,667,587
Designated Revenue Funds	21,513	14,666
Total Unrestricted Funds	1,799,804	1,682,253
Restricted Revenue Funds	19,701	20,145
Total Funds	1,819,505	1,702,398

Bankers

Unity Trust Bank, 9 Brindley Place, Birmingham, B1 2HB

CCLA Investment Management Ltd, COIF Charity Funds, Senator House, London

Royal London Asset Management, 55 Gracechurch Street, London

Solicitors

Stone King, 13 Queen Square, Bath, BA1 2HJ

Accountants

DR Hicks, Chartered Accountants, 107 Penn Hill Road, Bath, BA1 3RU

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.



BIRD's reserves policy is to

- Hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- Retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received and will encourage clinicians to undertake research and early stage career researchers. It will help thousands of patients to

understand their disease and treatment better and, with renewed focus, hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

Details of The Independent Examiner

Tom Case
Member of The Institute of Chartered Accountants in
England and Wales
20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY



Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP),

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- To prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 13-19.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016).



These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 20 September 2022.

Christopher Johns,
Chair



Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

I report to the Trustees on my examination of the financial statements of the charitable company on pages 13 to 19 for the year ended 31 March 2022 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 22.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 1, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- A.** Examine the financial statements of the charity under Section 145 of the Act;
- B.** Follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide. Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable

No material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

- Accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011
- The financial statements do not accord with those records; or the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination
- Have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:

A handwritten signature in black ink, appearing to read 'T. Case'.

Mr Tom Case, Independent Examiner

The Institute of Chartered Accountants in
England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

This report was signed on 20 September 2022.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

	SORP Ref	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Income & Endowments from:					
Donations & Legacies	A1	55,858	-	55,858	20,340
Charitable activities	A2	20,579	150	20,729	23,064
Investments	A4	47,199	-	47,199	49,315
Total income	A	123,636	150	123,786	92,719
Expenditure on:					
Charitable activities	B2	180,300	594	180,894	224,733
Total expenditure	B	180,300	594	180,894	224,733
Net gains on investments	B4	132,320	-	132,320	304,942
Net income for the year		75,656	(444)	75,212	172,928
Transfers between funds	C	-	-	-	-
Net income after transfers	A-B-C	75,656	(444)	75,212	172,928
Extraordinary items	D3	41,895	-	41,895	-
Net movement in funds		117,551	(444)	117,107	172,928
Reconciliation of funds:-					
Total funds brought forward	E	1,682,253	20,145	1,702,398	1,529,470
Total funds carried forward		1,799,804	19,701	1,819,505	1,702,398

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.

All activities derive from continuing operations.
The notes attached on pages 22 to 41 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Analysis of prior year total funds as required by paragraph 4.2 of the SORP.

	SORP REF	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £
Income & Endowments from:				
Donations & Legacies	A1	20,340	-	20,340
Charitable activities	A2	22,449	615	23,064
Investments	A4	49,315	-	49,315
Total income	A	92,104	615	92,719
Expenditure on:				
Charitable activities	B2	223,799	934	224,733
Total expenditure	B	223,799	934	224,733
Net gains on investments	B4	304,942	-	304,942
Net income for the year		173,247	(319)	172,928
Transfers between funds	C	2,085	(2,085)	-
Net income after transfers		175,332	(2,404)	172,928
Net movement in funds		175,332	(2,404)	172,928
Reconciliation of funds:-				
Total funds brought forward	E	1,506,921	22,549	1,529,470
Total funds carried forward		1,682,253	20,145	1,702,398

All activities derive from continuing operations.

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement.

The notes attached on pagesv form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Statement of Total Recognised Gains and Losses for the year ended 31 March 2022

	2022 £	2021 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(57,108)	(132,014)
	-	-
Income from operations before tax in the Statement of Financial Activities	(57,108)	(132,014)
Realised (losses)/gains on investments	(2,104)	16,967
Extraordinary items	41,895	-
Surplus as shown in the Income and Expenditure account	(17,317)	(115,047)
Unrealised (losses)/gains on investments	134,424	287,975
Net Movement in funds before taxation	117,107	172,928
Funds generated in the year as shown on Statement of Financial Activities	117,107	172,928

Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use

	2022 £	2022 £
Funds generated in the year as detailed in the SOFA	117,107	172,928
Resources applied on functional fixed assets	-	(1,260)
Net resources available to fund charitable activities	117,107	171,668

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use

Revenue accumulated funds	Unrestricted Funds 2022	Restricted Funds 2022	Total Funds 2022	Last year Total Funds 2021
	£	£	£	£
Accumulated funds brought forward	1,682,253	20,145	1,702,398	1,529,470
Recognised gains and losses before transfers	75,656	(444)	75,212	172,928
	1,757,909	19,701	1,777,610	1,702,398
Extraordinary items	41,895	-	41,895	-
Closing revenue funds	1,799,804	19,701	1,819,505	1,702,398

Designated revenue funds included within the unrestricted funds above

	Total Funds 2022	Last year Total Funds 2021
	£	£
At 1 April	14,666	14,595
Transfer (to)/from revenue accumulated funds	6,847	71
At 31 March	21,513	14,666

The purposes for which these funds have been designated are described in Note 22 to the accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Summary of funds

	Unrestricted and Designated Funds	Restricted Funds	Total Funds	Last Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Revenue accumulated funds	1,778,291	19,701	1,797,992	1,687,732
Revenue designated funds	21,513	-	21,513	14,666
Total funds	1,799,804	19,701	1,819,505	1,702,398

The notes attached on pages 22 to 41 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Income and Expenditure Account for the year ended 31 March 2022 as required by the Companies Act 2006

	2022	2021
	£	£
Income		
Income from operations	76,587	43,404
Realised gains/(losses) on investments	-	16,967
Investment income		
Income from investments, other than interest receivable	47,199	49,315
Gross income in the year before exceptional items	123,786	109,686
Gross income in the year including exceptional items	123,786	109,686
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	180,180	223,984
Depreciation and amortisation	276	329
Governance costs	438	420
Realised losses on the disposal of investments	2,104	-
Total expenditure in the year	182,998	224,733
Extraordinary items	41,895	-
Net income before tax in the financial year	(17,317)	(115,047)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(17,317)	(115,047)
Retained surplus for the financial year	(17,317)	(115,047)

All activities derive from continuing operations.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 22 to 41 form an integral part of these accounts.

Balance Sheet as at 31 March 2022



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

	Note	SORP Ref	2022 £	2021 £
Fixed assets		A		
Tangible assets	11	A2	943	1,219
Investments held as fixed assets	12	A4	1,736,569	1,602,145
Total fixed assets			<u>1,737,512</u>	<u>1,603,364</u>
Current assets		B		
Debtors	14	B2	18,284	9,798
Cash at bank and in hand		B4	151,545	259,598
Total current assets			<u>169,829</u>	<u>269,396</u>
Creditors: amounts falling due within one year	15	C1	<u>(87,836)</u>	<u>(170,362)</u>
Net current assets			81,993	99,034
The total net assets of the charity			<u>1,819,505</u>	<u>1,702,398</u>
The total net assets of the charity are funded by the funds of the charity, as follows:-				
Restricted funds				
Restricted Revenue Funds	19	D2	19,701	20,145
			19,701	20,145
Unrestricted Funds				
Unrestricted Revenue Funds	19	D3	1,778,291	1,667,587
			1,778,291	1,667,587
Designated Funds				
Designated Revenue Funds	19	D3	21,513	14,666
			21,513	14,666
Total charity funds			<u>1,819,505</u>	<u>1,702,398</u>



The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 11.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

A handwritten signature in black ink, reading "Jim Sherwin".

Mr JT Sherwin

Trustee and Chair of Finance Committee

Approved by the board of trustees on 20 September 2022.

Bath Institute for Rheumatic Diseases
Supporting Arthritis Research in Bath



Registered Charity 1040650
01225 336363 BIRD@birdbath.org.uk

Bath Institute
Rheumatic Diseases



1. Accounting Policies

Policies Relating to the Production of the Accounts

Basis of Preparation and Accounting Convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainties about the charity's ability to continue as a going concern.

Risks and Future Assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition

Nature of Income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income Recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.



Income from Legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities.

Policies relating to expenditure on goods and services provided to the charity.

Recognition of Liabilities and Expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.



Tangible Fixed Assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery - 20 % reducing balance.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial Instruments Including Cash and Bank Balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes. Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law. There are no endowment funds.

2. Liability to Taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3. Winding up or Dissolution of the Charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4. Significance of Financial Instruments to the Charity's Position

There are no significant implications of financial instruments to the charity's financial position or performance.

5. Net Surplus Before Tax in the Financial Year

The net surplus before tax in the financial year is stated after charging. Depreciation of owned fixed assets:

2022 = £276

2021 = £329



6. Investment Gains

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Realised gains/(losses)				
Listed investments	(2,104)	-	(2,104)	16,967
Total realised gains/(losses)	(2,104)	-	(2,104)	16,967
Unrealised gains /(losses) and writing down of carrying values				
Listed investments - Unrealised	134,424	-	134,424	287,975
Total unrealised gains/(losses) etc	134,424	-	134,424	287,975
Total realised and unrealised gains	132,320	-	132,320	304,942

All gains and losses in the prior year was unrestricted.

Prior Year:-

	Prior Year Unrestricted Funds 2021	Prior Year Restricted Funds 2021	Prior Year Total Funds 2021
	£	£	£
Realised gains/(losses)			
Listed investments	16,967	-	16,967
Total realised gains/(losses)	16,967	-	16,967
Unrealised gains /(losses) and writing down of carrying values			
Listed investments - Unrealised	287,975	-	287,975
Total unrealised gains/(losses) etc	287,975	-	287,975
Total realised and unrealised gains	304,942	-	304,942



7. Extraordinary items - analysed by fund

		2022	2021
		£	£
Unrestricted funds	(41,895)		
Restricted funds	-		
Total extraordinary items		(41,895)	-
		(41,895)	-

This item comprises £23,085 of a cancelled grant from previous years and £18,810 of an underspend from the funded clinical lectureship finishing earlier than awarded, due to promotion.

8. Staff costs and emoluments

Labour costs	2022	2021
	£	£
Gross salaries, labour and related costs	99,490	111,081
	99,490	111,081

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

9. Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.



10. Trustee's expenses

No trustee expenses were incurred, either in the current or prior year.

11. Tangible fixed assets

No trustee expenses were incurred, either in the current or prior year.

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2021	-	11,940	-	11,940
Additions	-	-	-	-
At 31 March 2022	-	11,940	-	11,940
Depreciation				
At 1 April 2021	-	10,721	-	10,721
Charge for the year	-	276	-	276
At 31 March 2022	-	10,997	-	10,997
Net book value				
At 31 March 2022	-	943	-	943
At 31 March 2021	-	1,219	-	1,219

12. Investments Held as Fixed Assets

	Investments in subsidiaries	Listed investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2021	2	1,602,143	-	1,602,145
Revaluation at 31 March 2022	-	134,424	-	134,424
At 31 March 2022	2	1,736,567	-	1,736,569
Analysis between fair value and historical cost				
Investments as above held at fair value	2	1,736,567	-	1,736,569



13. Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the seven years ending 31st March 2022.

A summary of the unaudited financial statements of the subsidiary is :-

	2022 £	2021 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)
Profit and Loss		
Net profit for the year before tax	-	-
Net profit for the year after tax and Gift Aid	-	-

Funds retained within charitable subsidiaries

	2022 £	2021 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	-	-



14. Debtors

	2022	2021
	£	£
Trade debtors	6,812	6,851
Prepayments and accrued income	11,472	2,947
	18,284	9,798

15. Creditors: amounts falling due within one year

	2022	2021
	£	£
Trade creditors	29,191	29,859
Accruals	600	600
Other creditors	58,045	139,903
	87,836	170,362

16. Income and Expenditure account summary

	2022	2021
	£	£
At 1 April 2021	1,414,423	1,529,470
Surplus after tax for the year	(17,317)	(115,047)
At 31 March 2022	1,397,106	1,414,423

17. No related party transactions

There were no transactions with related parties in the year.



**18. Particulars of How Particular Funds are
Represented by Assets and Liabilities**

At 31 March 2022	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Tangible Fixed Assets	943	-	-	943
Investments at valuation:-				
Fixed asset investments	1,736,569	-	-	1,736,569
Current Assets	128,615	21,513	19,701	169,829
Current Liabilities	(87,836)	-	-	(87,836)
	1,778,291	21,513	19,701	1,819,505
At 1 April 2021	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Tangible Fixed Assets	1,219	-	-	1,219
Investments at valuation:-				
Fixed asset investments	1,602,145	-	-	1,602,145
Current Assets	234,585	14,666	20,145	269,396
Current Liabilities	(170,362)	-	-	(170,362)
	1,667,587	14,666	20,145	1,702,398



19. Change in total funds over the year as shown in Note 18, analysed by individual funds

	Funds brought forward from 2021	Movement in funds in 2022	Transfers between funds in 2022	Funds carried forward to 2023
	£	See Note 20 £	See Note 21 £	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,667,587	117,551	(6,847)	1,778,291
Designated Revenue Funds	14,666	-	6,847	21,513
Total unrestricted and designated funds	1,682,253	117,551	-	1,799,804
Restricted funds:-				
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - CRPS Network UK	1,691	(594)	-	1,097
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Arthritis Grand Challenge	67	-	-	67
Restricted - Metabolic Bone Disease	3,121	150	-	3,121
Total restricted funds	20,145	(444)	-	19,701
Total charity funds	1,702,398	117,107	-	1,819,505



20. Analysis of movements in funds over the year as shown in Note 19

			Other	
	Income 2022 £	Expenditure 2022 £	Gains & Losses 2022 £	Movement in funds 2022 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	123,636	(180,300)	174,215	117,551
Restricted funds:-				
Restricted - CRPS Network UK		(594)	-	(594)
Restricted - Metabolic Bone Disease	150	-	-	150
	123,786	(180,894)	174,215	117,107

21. Details of transfers between

The transfers shown in note 18 above are:-	2022 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	(6,847)
To/(from) Designated Revenue Funds	6,847
To/(from) Restricted Revenue Funds	-
Net transfers	-

22. The purposes for which the funds

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds

Funds specific for this purpose.

Restricted Revenue Funds

Funds specific for this purpose.



23. Ultimate controlling party

The charity is under the control of its legal members. Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

24. Donations, Grants and Legacies

	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total Funds 2021
	£	£	£	£
Donations and gifts from individuals				
Donations	55,858	-	55,858	19,783
Total donations and gifts from individuals	55,858	-	55,858	19,783
	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total Funds 202
	£	£	£	£
Legacies receivable				
Legacies receivable	-	-	-	557
Total legacies receivable	-	-	-	557
Total Donations, Grants and Legacies	55,858	-	55,858	20,340

A1

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

25. Income from charitable activities - Trading Activities

Current year	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total funds 2021
	£	£	£	£
Primary purpose and ancillary trading				
Education income	625	-	625	341
Other and recharged income	3,465	150	3,615	675
Service charges - BGPRT	11,723	-	11,723	17,975
Service charges - BRIT PACT	4,766	-	4,766	4,073
Total Primary purpose and ancillary trading	20,579	150	20,729	23,064

Not all the trading activities in the prior year were unrestricted.

	Prior Year Unrestricted Funds 2021	Prior Year Restricted Funds 2021	Prior Year Total Funds 2021
Prior year	£	£	£
Primary purpose and ancillary trading			
Other and recharged income	60	615	675
Total Primary purpose and ancillary trading	22,449	615	23,064



26. Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Total income from charitable trading	20,579	150	20,729	23,064
Total from charitable activities	A2 20,579	150	20,729	23,064

Not all the income in the prior year was
unrestricted.

Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year 2021	Prior Year 2021	Prior Year 2021
	£	£	£
Total income from charitable trading	22,449	615	23,064
Income from funders	-	-	-
	22,449	615	23,064

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

27. Investment income

	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total funds 2021
	£	£	£	£
Dividend Income	47,199	-	47,199	49,315
Total investment income	A4 47,199	-	47,199	49,315

28. Expenditure on charitable activities - Direct spending

Current year	Current year Unrestricted Funds 2022	Current year Restricted Funds 2022	Current year Total Funds 2022	Prior Year Total Funds 2021
	£	£	£	£
Labour costs - charitable activities	99,490	-	99,490	111,081
Education costs	1,042	-	1,042	-
PPE Project costs	4,709	-	4,709	4,189
Travel and conferences	-	-	-	150
Total direct spending	B2a 105,241	-	105,241	115,420

Not all the income in the prior year was unrestricted.

Prior year	Prior Year 2021	Prior Year 2021	Prior Year 2021
	£	£	£
PPE Project costs	4,189	-	4,189
Total direct spending	B2a 115,420	-	115,420



29. Expenditure on charitable activities - grant funding of activities

<i>Current year</i>		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Grants made to individuals		55,047	-	55,047	78,688
Grant underspends from prior years		-	-	-	-
Total grantmaking costs	B2c	55,047	-	55,047	78,688

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

30. Support costs for charitable activities

Current Year	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Premises Expenses				
Rent	5,550	-	5,550	5,100
Administrative overheads				
Telephone, fax and internet	720	-	720	720
Stationery and printing	409	-	409	544
Marketing and promotion	1,174	-	1,174	3,078
Registration and licensing	657	-	657	653
IT support costs	1,288	-	1,288	1,237
Sundry expenses	168	-	168	28
Recharged expenses	4,119	594	4,713	1,715
Insurance	439	-	439	435
Hospitality	57	-	57	10
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	3,060	-	3,060	2,840
Other legal and professional	1,497	-	1,497	9,766
Financial costs				
Bank charges	160	-	160	157
Investment management costs	-	-	-	3,593
Depreciation & Amortisation in total for the period	276	-	276	329
Support costs before reallocation	19,574	594	20,168	30,205
Total support costs - Current Year	19,574	594	20,168	30,205

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Support costs for charitable activities cont.

Prior Year

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2021 £
Recharged expenses	781	934	1,715
Support costs before reallocation	29,271	934	30,205
Total support costs - Prior Year	29,271	934	30,205

31. Other Expenditure - Governance costs

Current Year

	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Fund 2022 £	Prior Year Total Funds 2021 £
Independent Examiner's fees	438	-	438	420
Trustees' expenses	-	-	-	-
Total Governance costs	438	-	438	420

All the expenditure in the prior year was unrestricted.

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

32. Total Charitable expenditure

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Total direct spending	B2a	105,241	-	105,241	115,420
Total grantmaking costs	B2c	55,047	-	55,047	78,688
Total support costs	B2d	19,574	594	20,168	30,205
Total Governance costs	B2e	438	-	438	420
Total charitable expenditure	B2	180,300	594	180,894	224,733

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2021	2021	2021
		£	£	£
Total direct spending	B2a	115,420	-	115,420
Total grantmaking costs	B2c	78,688	-	78,688
Total support costs	B2d	29,271	934	30,205
Total Governance costs	B2e	420	-	420
Total charitable expenditure	B2	223,799	934	224,733



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Annual Report and Accounts

31 March 2022

Accounts



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Annual Report and Accounts

31 March 2021

Company registration number 02908933 | Charity registration number 1040650



Contents

Charity Information	1
Trustees' Annual Report	1
Statement Of Directors' Responsibilities	9
Independent Examiner's Report	11
Funds Statements:	
Statement Of Financial Activities	13
Statement Of Financial Activities - Prior Year Statement	14
Statement Of Total Recognised Gains And Losses	15
Movements In Funds	17
Revenue Funds	18
Income And Expenditure Account	19
Balance Sheet	20
Notes To The Accounts	22



Trustees' Annual Report for the year ended 31 March 2021

The Trustees present their Report and Accounts for the year ended 31 March 2021, which also comprises the Directors' Report required by the Companies Act 2006.

Charity Name

The legal name of the charity is: Bath Institute for Rheumatic Diseases.

The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered with the Charity Commission in England & Wales (CCEW) with charity number 1040650.

The charity does not operate in any overseas jurisdictions.

Legal structure of the Charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:

Department D1
Wolfson Building, Royal United Hospital
Bath
BA1 3NG
Telephone: 01225 336363
Email Address: BIRD@birdbath.org.uk
Web Address: www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in Office on the Date the Report was Approved were:

Dr N Hall
Mr C Johns (Chair)
Mr J Sherwin
Dr A Mackenzie
Dr R Sengupta
Dr J Pauling
Dr W Tillett
Ms S Lear
Prof N McHugh



Trustees' Annual Report for the year ended 31 March 2021 continued

Objects and Activities of the Charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

In November 2020 the Articles of Association for BIRD were updated, mainly along the lines of the Charity Commission's model constitution. This was last done in 1994. Nineteen previous trustees were contacted to ensure clarity over the members' register since part of the update was to provide that the only "members" will be the trustees, so that any change in the trustees automatically updates the changes in the membership. The changes were adopted unanimously and the new Articles were given consent by the Charity Commission.

Response to the Covid 19 pandemic

The country was in lockdown in response to the Covid 19 pandemic by the period starting this report. This had impacted BIRD's plans considerably. All live events (Patient engagement days and Education seminars for Healthcare Professionals, also the annual fundraising/awareness raising event) were cancelled and the office was closed. Consultant Trustees and other healthcare professionals on BIRD's committees were pulled into patient care on the wards. Laboratories were closed and opened up only gradually during the year with improved social distancing, causing bottlenecks and delays to projects.

BIRD's response was to switch all staff to working from home, a pre-existing arrangement for many contractors. Instead of the programme of patient information days across a range of rheumatic disease areas, this was replaced by, initially, a trial of podcast interviews with specialists available to listeners via an online platform, Anchor. To ensure the widest possible reach, these were advertised on Facebook using a specialist agency, as well as promoted to patients via the usual e-newsletter and postal mailings. Following successful results in terms of numbers reached, listening length and qualitative feedback (details below), a programme of podcasts was developed and launched over the year, creating a new library resource for patients on BIRD's website.

To address the difficulties in conducting research when laboratory access was restricted or patient recruitment suspended, the Research Committee decided to write proactively to all live funded projects to offer support. As a result, many time extensions were granted and five cost extensions, amounting to £23,216.50 to allow the projects to proceed. BIRD has received many plaudits for this support and understanding of the difficulties that researchers faced during the pandemic.

The education programme for consultants, GPs, nurses and physiotherapists was also switched from in-person to online training. While numbers attending increased significantly, pharmaceutical companies were not able to sponsor virtual meetings due to their internal policies, impacting BIRD's income.

The planned Autumn awareness raising and fundraising event was deferred and other methods of raising awareness implemented instead (see below).



Trustees' Annual Report for the year ended 31 March 2021 continued



Grants awarded for Research

BIRD funds research projects in rheumatic diseases which:

- Help to promote and advance medical knowledge
- Improve treatments for patients
- Encourage collaboration between clinicians and research scientists
- Supports the next generation of researchers into bone and joint diseases

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £10,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

In total, **£78,823.50** was awarded:

- £11,500 to Dr Jennifer Rosedale to investigate the role of the micro-biome in people with Pulmonary Hypertension as a frequently fatal complication of Systemic Sclerosis, to help predict those who are more at risk of developing it, and to develop treatments
- £20,000 to Dr Fiona Gillison to research best practice in digital technology delivery of patient care in rheumatology, on the experience during the COVID-19 pandemic to maximise virtual consultations

- £23,216.50 to cover cost extensions of live projects impacted by the pandemic
- £24,107 towards Dr Sarah Tansley's National Institute for Health Research Clinical Lectureship, each year for three years

Grant programme evaluation report

During the year, BIRD's research grant programme was evaluated by Ben Hutchinson, member of the Research Committee, analysing the success of all grant making activity from 2016 to 2020. It was based on findings from interviews with grant recipients, Research Committee members, consultant trustees, and BIRD staff.

BIRD funding has supported clinicians from Rheumatology, Cardiology, Radiology, Respiratory, and Pulmonary Hypertension at the RUH, and in other leading centres including Leeds Children's Hospital, and Alder Hey Children's Hospital, enabling them to build their research portfolios.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

537 patients have been involved in a meaningful way on BIRD-funded projects, including in the design stage and as participants.

BIRD has funded 18 projects since 2016: 11 pump-priming projects, 3 matched PhD studentships, 3 adding value to large grants; and a series of summer studentships.

BIRD has helped to advance medical science, with grants generating at least 20 academic publications so far.



Trustees' Annual Report for the year ended 31 March 2021 continued

Areas in which BIRD can increase its outputs, outcomes and impact, were outlined as recommendations which the Research Committee has taken responsibility for taking forward.



BIRD's education programme for Healthcare Professionals

BIRD organises a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal National Hospital for Rheumatic Diseases, (based at the Royal United Hospital, Bath) the University of Bath and the Bath GP Education & Research Trust.

BIRD provided the administration, support, including the accreditation and sponsorship where necessary, for educational events reaching 254 healthcare professionals.

Each of the training sessions was approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

This year, BIRD was unable to secure sponsorship for the education programme due to covid restrictions and compliance with pharmaceutical companies' internal policies regarding virtual meetings. BIRD hopes to resume securing funding for future face to face events when possible. The South West CTD Vasculitis Group Meeting was held online on 15th September 2020 and 16th March 2021 instead of in person.

The Primary Care Rheumatology Update was held online on 6th October 2020 instead of in person.

New Rheumatology Research group meetings were instituted to bring together researchers at the University and clinicians at the hospital and to update one another on two new projects at a time. These were scheduled quarterly and very well attended and received.

All meetings ran successfully with higher numbers of attendees on average than face to face meetings with 254 attendees in total during this financial year. In 2019/20, 300 healthcare professionals attended. However, two meetings, the Bath and Bristol Weston Axial Spondyloarthritis meeting and the Bath and Bristol Bone meeting were postponed in Autumn 2020 due to the pandemic. It is envisaged that a combination of face to face and virtual meetings will be organised in future.

Dr Andrew Allard, consultant rheumatologist, joined the Education and Engagement committee to help shape the Education Programme with Senior Administrator Fran Staples.



The Patient and Public Engagement Programme

The vision is 'to help more patients to be involved in research and deepen their understanding of Rheumatic Diseases, the latest research and treatment'. Phase two of the programme commenced in October 2020, to reach a wider spectrum of the population and for 85% of patient users to deepen their understanding and to encourage at least 150 more patients in research and build their confidence in participation. Specifically, this would be done



Trustees' Annual Report for the year ended 31 March 2021 continued

through creating a library of podcasts across nine rheumatic disease areas with over 2,000 listens, holding three live events with at least 200 attendees in total, growing the database to 600 patients, promoting research opportunities, producing three patient case studies, setting up a patient research panel, providing support to researchers for at least six focus groups or workshops, issuing at least eight surveys.

To the end of March 2021, 6 rheumatic disease areas had been covered (Scleroderma, Axial Spondyloarthritis, Young Adults, Vasculitis, Osteoporosis and Myositis) by 20 podcasts and an impressive 5,228 listens. The database stood at 533. Eight research opportunities had been promoted and researchers advised. A virtual workshop was held on the theme of 'Coping with a rheumatic condition during the Coronavirus lockdown'.

Awareness Raising

The reach of BIRD was expanded exponentially through the investment in Facebook advertising for the podcasts, with over 200,000 people getting the opportunity to see a BIRD advertisement for the podcasts. Reactions (likes and comments) led to an invitation to like the BIRD Facebook page and encouragement to sign up to the e-newsletter database. The database is segmented into patients' interest by disease area and stakeholders.

A new general leaflet and a 90 second animation of BIRD's core purpose and recent results was produced in order to reach stakeholders on LinkedIn in particular.

A sculpted bird bath was craned into place outside the new Royal National Hospital for Rheumatic Diseases at the Royal United Hospital, on 10 September 2020. It is dedicated to the donors supporting Bath Institute for Rheumatic Diseases (BIRD) by funding scientific and clinical research since 1975 and marks the charity's relocation to the hospital site. The artwork is

called 'Ascending' and was sculpted by skilled stonemason Steve Hall from natural Bath stone. A brass plaque also thanking donors was installed in the RNHRD waiting room.

Dr Ben Mulhearn, Rheumatology Clinical Academic Trainee, started training for running the Palma half marathon in October 2021 to raise funds for BIRD. He said: "With family links to rheumatoid arthritis and working in the field (as well as having a dodgy knee), this is my way to both raise money for rheumatology research and raise awareness of the discipline of rheumatology, as well as having a great time while doing so". By the end of March, he had already raised £672.

Particular effort was spent in seeking to attract grants from Pharma companies for the Patient Engagement programme and resulting in one new company supporting it. However, the significant success of the reach of the podcast programme was not evident until after that round of applications, and the track record of attracting thousands of listeners may yet prove attractive to further sponsorship.

Grants were awarded to the Patient and Public Engagement programme by the Champriss Charitable Trust, The Sperring Charity, HealthWatch, Eli Lilly and Company Ltd and UCB (the latter negotiated and agreed but will show in the following year's accounts).

The main achievements and performance of the charity in terms of public benefit were:

- The total amount of grants awarded for research into rheumatic diseases was £78,823.50
- 254 attendees at training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics
- 5,228 listens to podcasts for patients. The total



Trustees' Annual Report for the year ended 31 March 2021 continued

network reached via mailings and social media ad postings was estimated at almost 200,000 patients and members of the public. The investment in paid advertising promoted by a specialist agency explains this exponential increase

- 76% of listeners to podcasts understood their condition better as result
- Awareness raising continued to grow through advertising, e-newsletter engagement and stakeholder relations with the University and Hospital
- Fundraising continued to struggle at only £1,435 donations and £18,348 grants awarded, despite 75 grant applications written and a new emphasis on seeking pharma funding for the patient engagement programme. However, the latter was hampered by seeking pharma funding before the switch to podcasts had proved a demonstrable success in reaching so many people

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.

Structure, Governance and Management of the Charity

The governing body is the Council of Management made up of 9 trustees. The chair is Chris Johns. Council of Management meets quarterly. Three committees report in to the Council of Management. These are the quarterly Finance Committee (renamed in 2019 from the Finance and Investment Group), chaired by Jim Sherwin, members are Dr Nick Hall, Dr Linda McHugh, Chris Johns and Linda Snelus; the biannual Research Committee (renamed in 2019 from the Research Assessment

Group), chaired by Dr Nick Hall, members are Dr Lisa Austin, Professor Rod Flower, Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr John Pauling, Dr Sarah Skeoch, Frank Sweeting; and the quarterly Education & Engagement Committee (renamed in 2019 from the Patient Liaison and Fundraising Group), chaired by Stephanie Lear, members are Dr Andrew Allard, Judy Coles and Dr Patrick Ismond. All committees are supported by relevant contract staff in attendance.

Bankers:

Unity Trust Bank
9 Brindley Place, Birmingham B1 2HB

CCLA Investment Management Ltd
COIF Charity Funds, Senator House, London

Royal London Asset Management
55 Gracechurch Street, London

Investec Wealth & Investment
30 Gresham Street, London EC2V 7QN

Solicitors:

Stone King
13 Queen Square, Bath BA1 2HJ

Accountants:

DR Hicks
Chartered Accountants
107 Penn Hill Road, Bath BA1 3RU



Trustees' Annual Report for the year ended 31 March 2021 continued

Financial Review

The financial position of the charity at 31 March 2021 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:

	2021	2020
	£	£
Net income	172,928	(239,501)
Unrestricted Revenue Funds available for the general purposes of the charity	1,667,587	1,492,326
Designated Revenue Funds	14,666	14,595
Total Unrestricted Funds	1,682,253	1,506,921
Restricted Revenue Funds	20,145	22,549
Total Funds	1,702,398	1,529,470

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.

BIRD's Reserves Policy is to:

- Hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies
- Retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time,

such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised. Dividends and interest are paid away on a quarterly basis.



Trustees' Annual Report for the year ended 31 March 2021 continued

Summary of plans for the future and the trustees' perspective of the future direction of the charity

BIRD remains committed to funding research into rheumatic diseases at a level of £80,000 minimum. It will encourage thousands of patients to understand their disease better and hundreds to engage with research. It will also continue to maintain and develop the education programme for healthcare professionals.

For the future, BIRD will be taking forward the first phase of recommendations from the research grant evaluation report. Specifically, in the next year, to:

- Introduce a light touch process for capturing evidence of mid- to long term impact of its funding, capturing publications, follow on funding and real-world impact via email at 3- and 5-years post project
- Continue to build on significant success in pump-priming research
- Encourage proposals from allied health professionals
- Add a panel member with social sciences/ qualitative research expertise to the Research Committee
- Explore novel ways of telling stories about funded research, for example, capturing testimonies of patients involved in research
- Encourage patient co-authored papers, where appropriate
- Explore the availability of a space within the RUH to enable 'hot-desking' of academic researchers to facilitate research meetings between academic and clinical researchers

- Run an annual or bi-annual conference for clinicians, researchers, allied health professionals, PhD students, patients, and other stakeholders

The Patient Engagement programme will continue to evolve and evaluate success, exploring new methods of virtual delivery if live events are not advisable. The third phase of the programme will be in development over the year ahead commencing late Spring 2022.

This year, the strong performance of investments meant that the gain on the value of investments was £304,942 resulting in a net income position for unrestricted funds of £175,332. The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. However, the achievements of the last few years in fundraising experiments remain modest. The experiment in bringing in specialist advice on pharma fundraising will continue another year to maximise opportunities from the increased numbers of patients reached through advertising podcasts, and a new trial of emphasis on legacy fundraising will take place over the next year.

Details of The Independent Examiner

Mr Tom Case
Member of The Institute of Chartered Accountants
in England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY



Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- To prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law)
- Select suitable accounting policies and apply them consistently
- Make judgements and estimates that are reasonable and prudent

- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business
- State whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that, on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.



Method of preparation of accounts - Small Company Provisions

The financial statements are set out on pages 13-41.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016).

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 28 September 2021.

A handwritten signature in black ink, reading "Christopher Johns".

Christopher Johns,

Chair



Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2021

I report to the Trustees on my examination of the financial statements of the charitable company on pages 13 to 19 for the year ended 31 March 2021 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 22.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 9, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence,

the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- A)** Examine the financial statements of the charity under Section 145 of the Act
- B)** Follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act

Basis of independent examiner's statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.



Report of the independent examiner to the trustees of the charitable company on the accounts for the year ended 31 March 2021 continued

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable

No material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- Accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011
- The financial statements do not accord with those records; or the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination
- Have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015,

(as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:

Mr Tom Case, Independent Examiner

The Institute of Chartered Accountants in
England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

This report was signed on 28 September 2021.



Statement of financial activities for the year ended 31 March 2021

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	20,340	-	20,340	12,731
Charitable activities	A2	22,449	615	23,064	47,602
Investments	A4	49,315	-	49,315	62,591
Total income	A	92,104	615	92,719	122,924
Expenditure on:					
Charitable activities	B2	223,799	934	224,733	255,462
Total expenditure	B	223,799	934	224,733	255,462
Net gains on investments	B4	304,942	-	304,942	(106,963)
Net income for the year		173,247	(319)	172,928	(239,501)
Transfers between funds	C	2,085	(2,085)	-	-
Net income after transfers	A-B-C	175,332	(2,404)	172,928	(239,501)
Net movement in funds		175,332	(2,404)	172,928	(239,501)
Reconciliation of funds:-					
Total funds brought forward	E	1,506,921	22,549	1,529,470	1,768,971
Total funds carried forward		1,682,253	20,145	1,702,398	1,529,470

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts. All activities derive from continuing operations



Statement of financial activities for the year ended 31 March 2021 continued

Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP REF	Prior Year Unrestricted Funds 2020 £	Prior Year Restricted Funds 2020 £	Prior Year Total Funds 2020 £
Income & Endowments from:				
Donations & Legacies	A1	12,731	-	12,731
Charitable activities	A2	46,014	1,588	47,602
Other trading activities	A3	-	-	-
Investments	A4	62,591	-	62,591
Other	A5	-	-	-
Total income	A	121,336	(1,588)	122,924
Expenditure on:				
Raising funds	B1	-	-	-
Charitable activities	B2	254,530	932	255,462
Other	B3	-	-	-
Tax on surplus on ordinary activity	B3	-	-	-
Other taxation	B3	-	-	-
Total expenditure	B	254,530	932	255,462
Net gains on investments	B4	(106,963)	-	(106,963)
Net income for the year		(240,157)	656	(239,501)
Transfers between funds	C	1,616	(1,616)	-
Net income after transfers		(238,541)	(960)	(239,501)
Reconciliation of funds		(238,541)	(960)	(239,501)
Reconciliation of funds:-				
Total funds brought forward	E	1,745,462	23,509	1,768,971
Total funds carried forward		1,506,921	22,549	1,529,470

All activities derive from continuing operations.

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement.



Statement of financial activities for the year ended 31 March 2021 continued

Statement of Total Recognised Gains and Losses for the year ended 31 March 2021

	2021	2020
	£	£
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(132,014)	(132,538)
	-	-
Income from operations before tax in the Statement of Financial Activities	(132,014)	(132,538)
Realised (losses)/gains on investments	16,967	(18,110)
Surplus as shown in the Income and Expenditure account	(115,047)	(150,648)
Unrealised (losses)/gains on investments	287,975	(88,853)
Net Movement in funds before taxation	172,928	(239,501)
Funds generated in the year as shown on Statement of Financial Activities	172,928	(239,501)



Statement of financial activities for the year ended 31 March 2021 continued

Resources applied in the year ended 31 March 2021 towards fixed assets for Charity use

	2021	2020
	£	£
Funds generated in the year as detailed in the SOFA	172,928	(239,501)
Resources applied on functional fixed assets	(1,260)	(119)
Net resources available to fund charitable activities	171,668	(239,620)



Statement of financial activities for the year ended 31 March 2021 continued

Movements in Revenue and Capital Funds for the Year Ended 31 March 2021

Revenue accumulated funds	Unrestricted Funds 2021	Restricted Funds 2021	Total Funds 2021	Last year Total Funds 2020
	£	£	£	£
Accumulated funds brought forward	1,506,921	22,549	1,529,470	1,768,971
Recognised gains and losses before transfers	173,247	(319)	172,928	(239,501)
	1,680,168	22,230	1,702,398	1,529,470
(From)/To unrestricted revenue funds	2,085	(2,085)	-	-
Closing revenue funds	1,682,253	20,145	1,702,398	1,529,470

Designated revenue funds included within the unrestricted funds above

	Total Funds 2021	Last year Total Funds 2020
	£	£
At 1 April	14,595	35,887
Transfer (to)/from revenue accumulated funds	71	(21,292)
At 31 March	14,666	14,595



Statement of financial activities for the year ended 31 March 2021 continued

Movements in Revenue and Capital Funds for the Year Ended 31 March 2021

Summary of funds

	Unrestricted and Designated Funds	Restricted Funds	Total Funds	Last Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Revenue accumulated funds	1,667,587	20,145	1,687,732	1,514,875
Revenue designated funds	14,666	-	14,666	14,595
Total funds	1,682,253	20,145	1,702,398	1,529,470



Statement of financial activities for the year ended 31 March 2021 continued

Income and Expenditure Account for the year ended 31 March 2021 as required by the Companies Act 2006

	2021	2020
	£	£
Income		
Income from operations	43,404	60,333
Realised gains on investments	16,967	(18,110)
Investment income		
Income from investments, other than interest receivable	49,315	62,591
Gross income in the year before exceptional items	109,686	104,814
Gross income in the year including exceptional items	109,686	104,814
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	223,984	254,244
Depreciation and amortisation	329	588
Governance costs	420	630
Total expenditure in the year	224,733	255,462
Net income before tax in the financial year	(115,047)	(150,648)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(115,047)	(150,648)
Retained surplus for the financial year	(115,047)	(150,648)

All activities derive from continuing operations.

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.



Balance Sheet as at 31 March 2021

	Note	SORP Ref	2021 £	2020 £
Fixed assets		A		
Tangible assets	10	A2	1,219	288
Investments held as fixed assets	11	A4	1,602,145	1,314,170
Total fixed assets			<u>1,603,364</u>	<u>1,314,458</u>
Current assets		B		
Debtors	13	B2	9,798	11,281
Cash at bank and in hand		B4	259,598	460,491
Total current assets			<u>269,396</u>	<u>471,772</u>
Creditors: amounts falling due within one year	14	C1	<u>(170,362)</u>	<u>(256,760)</u>
Net current assets			99,034	215,012
The total net assets of the charity			<u>1,702,398</u>	<u>1,529,470</u>
The total net assets of the charity are funded by the funds of the charity, as follows:-				
Restricted funds				
Restricted Revenue Funds	18	D2	20,145	22,549
			20,145	22,549
Unrestricted Funds				
Unrestricted Revenue Funds	18	D3	1,667,587	1,492,326
			1,667,587	1,492,326
Designated Funds				
Designated Revenue Funds	18	D3	14,666	14,595
			14,666	14,595
Total charity funds			<u>1,702,398</u>	<u>1,529,470</u>



Balance Sheet as at 31 March 2021

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on [page 11](#).

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

A handwritten signature in black ink, appearing to read 'Jim Sherwin'.

Mr JT Sherwin

Trustee and Chair of Finance Committee

Approved by the board of trustees on 28 September 2021.



Notes to the accounts for the year ending 31 March 2021

1. Accounting Policies

Policies Relating to the Production of the Accounts

Basis of Preparation and Accounting Convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainties about the charity's ability to continue as a going concern.

Risks and Future Assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition

Nature of Income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income Recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.



Notes to the accounts for the year ending 31 March 2021 continued

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from Legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities.

Policies relating to expenditure on goods and services provided to the charity.

Recognition of Liabilities and Expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.



Notes to the accounts for the year ending 31 March 2021 continued

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible Fixed Assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery - 20 % reducing balance.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in accordance with the guidance given in the SORP.

Financial Instruments Including Cash and Bank Balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes. Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law. There are no endowment funds.

2. Liability to Taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3. Winding up or Dissolution of the Charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4. Significance of Financial Instruments to the Charity's Position

There are no significant implications of financial instruments to the charity's financial position or performance.

5. Net Surplus Before Tax in the Financial Year

The net surplus before tax in the financial year is stated after charging. Depreciation of owned fixed assets:

2021 = £329

2020 = £588



Notes to the accounts for the year ending 31 March 2021 continued

6. Investment Gains

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Realised gains/(losses)				
Listed investments	16,967	-	16,967	(18,110)
Total realised gains/(losses)	16,967	-	16,967	(18,110)
Unrealised gains/(losses) and writing down of carrying values				
Listed investments - Unrealised	287,975	-	287,975	(88,853)
Total unrealised gains/(losses) etc	287,975	-	287,975	(88,853)
Total realised and unrealised gains	304,942	-	304,942	(106,963)

All gains and losses in the prior year was unrestricted.

Prior Year :-

	Prior Year Unrestricted Funds 2020	Prior Year Restricted Funds 2020	Prior Year Total Funds 2020
	£	£	£
Realised gains/(losses)			
Listed investments	(18,110)	-	(18,110)
Total realised gains/(losses)	(18,110)	-	(18,110)
Unrealised gains/(losses) and writing down of carrying values			
Listed investments - Unrealised	(88,853)	-	(88,853)
Total unrealised gains/(losses) etc	(88,853)	-	(88,853)
Total realised and unrealised gains	(106,963)	-	(106,963)



Notes to the accounts for the year ending 31 March 2021 continued

7. Staff Costs and Emoluments

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

Labour costs	2021	2020
	£	£
Gross salaries, labour and related costs	111,081	113,458
	111,081	113,458

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8. Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

9. Trustees' expenses

The expenses reimbursed to trustees, or paid directly to third parties, in the current or prior year, was as shown below.

The amount reimbursed to trustees:

2021 = nil

2020 = £228

The nature of the trustees' expenses in 2020 was for travel expenses.

The number of trustees' in 2020 to whom expenses were reimbursed was 1.



Notes to the accounts for the year ending 31 March 2021 continued

10. Tangible Fixed Assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2020	-	10,680	-	10,680
Additions		1,260		1,260
At 31 March 2021	-	11,940	-	11,940
Depreciation				
At 1 April 2020	-	10,392	-	10,392
Charge for the year	-	329	-	329
At 31 March 2021	-	10,721	-	10,721
Net book value				
At 31 March 2021	-	1,219	-	1,219
At 31 March 2020	-	288	-	288

11. Investments Held as Fixed Assets

	Investments in subsidiaries	Listed investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2020	2	1,314,168	-	1,314,170
Revaluation at 31 March 2021	-	287,975	-	287,975
At 31 March 2021	2	1,602,143	-	1,602,145
Analysis between fair value and historical cost				
Investments as above held at fair value	2	1,602,143	-	1,602,145



Notes to the accounts for the year ending 31 March 2021 continued

12. Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the six years ending 31st March 2021.

A summary of the unaudited financial statements of the subsidiary is :-

	2021 £	2020 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)
Profit and Loss		
Net profit for the year before tax	-	-
Net profit for the year after tax and Gift Aid	-	-

Funds retained within charitable subsidiaries

	2021 £	2020 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	-	-



Notes to the accounts for the year ending 31 March 2021 continued

13. Debtors

	2021 £	2020 £
Trade debtors	6,851	4,846
Prepayments and accrued income	2,947	6,435
	9,798	11,281

14. Creditors: Amounts Falling Due Within One Year

	2021 £	2020 £
Trade creditors	29,859	13,021
Accruals	600	5,829
Other creditors	139,903	237,910
	170,362	256,760

15. Income and Expenditure account summary

	2021 £	2020 £
At 1 April 2020	1,618,323	1,768,971
Surplus after tax for the year	(115,047)	(150,648)
At 31 March 2021	1,503,276	1,618,323

16. No related party transactions

There were no transactions with related parties in the year.



Notes to the accounts for the year ending 31 March 2021 continued

17. Particulars of How Particular Funds are Represented by Assets and Liabilities

At 31 March 2021	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Tangible Fixed Assets	1,219	-	-	1,219
Investments at valuation:-				
Fixed asset investments	1,602,145	-	-	1,602,145
Current Assets	234,585	14,666	20,145	269,396
Current Liabilities	(170,362)	-	-	(170,362)
	1,667,587	14,666	20,145	1,702,398
At 1 April 2020	Unrestricted funds £	Designated funds £	Restricted funds £	Total funds £
Tangible Fixed Assets	288	-	-	288
Investments at valuation:-				
Fixed asset investments	1,314,170	-	-	1,314,170
Current Assets	434,628	14,595	22,549	471,772
Current Liabilities	(256,760)	-	-	(256,760)
	1,492,326	14,595	22,549	1,529,470



Notes to the accounts for the year ending 31 March 2021 continued

18. Change in Total Funds Over The Year as Shown in Note 17, Analysed By Individual Funds

	Funds brought forward from 2020	Movement in funds in 2021	Transfers between funds in 2021	Funds carried forward to 2022
		See Note 19	See Note 20	
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,492,326	173,247	2,014	1,667,587
Designated Revenue Funds	14,595	-	71	14,666
Total unrestricted and designated funds	1,506,921	173,247	2,085	1,682,253
Restricted funds:-				
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - CRPS Network UK	2,085	(394)	-	1,691
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Non comm trials	2,085	-	(2,085)	-
Restricted - Arthritis Grand Challenge	67	-	-	67
Restricted - Metabolic Bone Disease	3,046	75	-	3,121
Total restricted funds	22,549	(319)	(2,085)	20,145
Total charity funds	1,529,470	172,928	-	1,702,398



Notes to the accounts for the year ending 31 March 2021 continued

19. Analysis of Movements in Funds Over the Year as Shown in Note 18

	Income 2021 £	Expenditure 2021 £	Other Gains & Losses 2021 £	Movement in funds 2021 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	92,104	(223,799)	304,942	173,247
Restricted funds:-				
Restricted - CRPS Network UK	540	(934)	-	(394)
Restricted - Metabolic Bone Disease	75	-	-	75
	92,719	(224,733)	304,942	172,928

20. Details of Transfers Between Funds

The transfers shown in note 18 above are:-	2021 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	2,014
To/(from) Designated Revenue Funds	71
To/(from) Restricted Revenue Funds	(2,085)
Net transfers	-

21. The Purposes of which the Funds:

Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds

Funds specific for this purpose.

Restricted Revenue Funds

Funds specific for this purpose.



Notes to the accounts for the year ending 31 March 2021 continued

22. Ultimate controlling party

The charity is under the control of its legal members. Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

23. Donations, Grants and Legacies

	Current year Unrestricted Funds 2021	Current year Restricted Funds 2021	Current year Total Funds 2021	Prior Year Total Funds 2020
	£	£	£	£
Donations and gifts from individuals				
Donations	19,783	-	19,783	17,749
Total donations and gifts from individuals	19,783	-	19,783	17,749
	Current year Unrestricted Funds 2021	Current year Restricted Funds 2021	Current year Total Funds 2021	Prior Year Total Funds 2020
	£	£	£	£
Legacies receivable				
Legacies receivable	557	-	557	(5,018)
Total legacies receivable	557	-	557	(5,018)
This negative figure is explained by an over accrual made for legacy income in the prior year.				
Total Donations, Grants and Legacies	20,340	-	20,340	12,731

A1



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

24. Income from charitable activities - Trading Activities

Current year	Current year Unrestricted Funds 2021	Current year Restricted Funds 2021	Current year Total Funds 2021	Prior Year Total funds 2020
	£	£	£	£
Primary purpose and ancillary trading				
Education income	341	-	341	21,905
Other and recharged income	60	615	675	2,928
Service charges - BGPRT	17,975	-	17,975	15,457
Service charges - BRIT PACT	4,073	-	4,073	7,312
Total Primary purpose and ancillary trading	22,449	615	23,064	47,602
Not all the trading activities in the prior year were unrestricted				
Prior year	Prior Year Unrestricted Funds 2020	Prior Year Restricted Funds 2020	Prior Year Total Funds 2020	
	£	£	£	
Primary purpose and ancillary trading				
Other and recharged income	1,340	1,588	2,928	
Total Primary purpose and ancillary trading	46,014	1,588	47,602	



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

25. Total Income from charitable activities

<i>Current year</i>	Current year Unrestricted Funds 2021	Current year Restricted Funds 2021	Current year Total Funds 2021	Prior Year Total Funds 2020
	£	£	£	£
Total income from charitable trading	22,449	615	23,064	47,602
Total from charitable activities	A2 22,449	615	23,064	47,602

Income from charitable activities - Prior Year analysis

<i>Prior year</i>	Prior Year 2020	Prior Year 2020	Prior Year 2020
	£	£	£
Total income from charitable trading	46,014	1,588	47,602
	-	-	-
	46,014	1,588	47,602



Detailed analysis of income and expenditure for the year ended 31 March 2020 as required by the SORP 2015 continued

26. Investment income

		Current year Unrestricted Funds 2021 £	Current year Restricted Funds 2021 £	Current year Total Funds 2021 £	Prior Year Total Funds 2020 £
Dividend Income		49,315	-	49,315	62,591
Total investment income	A4	49,315	-	49,315	62,591

27. Expenditure on charitable activities — Direct spending

<i>Current year</i>		Current year Unrestricted Funds 2021 £	Current year Restricted Funds 2021 £	Current year Total Funds 2021 £	Prior Year Total Funds 2020 £
Labour costs - charitable activities		111,081	-	111,081	113,458
Education costs		-	-	-	20,299
PPE Project costs		4,189	-	4,189	7,310
Travel and conferences		150	-	150	459
Total direct spending	B2a	115,420	-	115,420	141,526

Not all the expenditure in the prior year was unrestricted.

<i>Prior year</i>		Prior Year Unrestricted Funds 2020 £	Prior Year Restricted Funds 2020 £	Prior Year Total Funds 2020 £
Education costs		20,166	133	20,299
PPE Project costs		6,812	498	7,310
Total direct spending	B2a	140,895	631	141,526



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

28. Expenditure on charitable activities — Grant funding of activities

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Grants made to individuals		78,688	-	78,688	82,597
Total grantmaking costs	B2c	78,688	-	82,597	82,597

29. Support costs for charitable activities

<i>Current Year</i>		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Premises Expenses					
Rent		5,100	-	5,100	4,200
Administrative overheads					
Telephone, fax and internet		720	-	720	1,100
Stationery and printing		544	-	544	771
Marketing and promotion		3,078	-	3,078	4,046
Registration and licensing		653	-	653	295
IT support costs		1,237	-	1,237	3,645
Sundry expenses		28	-	28	146
Recharged expenses		781	934	1,715	1,737
Insurance		435	-	435	435
Hospitality		10	-	10	284

Professional fees paid to the Auditor or Independent Examiner in addition to audit and examination fees



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

29. Support costs for charitable activities cont.

Current Year	Current year Unrestricted Funds 2021 £	Current year Restricted Funds 2021 £	Current year Total Funds 2021 £	Prior Year Total Funds 2020 £
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	2,840	-	2,840	3,360
Other legal and professional	9,766	-	9,766	1,634
Financial costs				
Bank charges	157	-	157	178
Investment management costs	3,593	-	3,593	8,290
Depreciation & Amortisation in total for the period	329	-	329	588
Support costs before reallocation	29,271	934	30,205	30,709
Total support costs - Current Year	29,271	934	30,205	30,709

All the expenditure in the prior year was unrestricted.

Prior Year	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2020 £
Recharged expenses	1,436	301	1,737
Support costs before reallocation	30,408	301	30,709
Total support costs - Prior Year	30,408	301	30,709



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

30. Other Expenditure — Governance costs

<i>Current Year</i>	Current year Unrestricted Funds 2021	Current year Restricted Funds 2021	Current year Total Fund 2021	Prior Year Total Funds 2020
	£	£	£	£
Independent Examiner's fees	420	-	420	402
Trustees' expenses	-	-	-	228
Total Governance costs	420	-	420	630

All the expenditure in the prior year was unrestricted.



Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015 continued

31. Total Charitable expenditure

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Total direct spending	B2a	115,420	-	115,420	141,526
Total grantmaking costs	B2c	78,688	-	78,688	82,597
Total support costs	B2d	29,271	934	30,205	30,709
Total Governance costs	B2e	420	-	420	630
Total charitable expenditure	B2	223,799	934	224,733	255,462

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds	
		2020	2020	2020	
		£	£	£	
Total direct spending	B2a	140,895	631	141,526	
Total grantmaking costs	B2c	82,597	-	82,597	
Total support costs	B2d	30,408	301	30,709	
Total Governance costs	B2e	630	-	630	
Total charitable expenditure	B2	254,530	932	255,462	



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Annual Report and Accounts

31 March 2021

Company registration number 02908933 | Charity registration number 1040650